

Author Index for 1990-91

- Alexandropoulos, K. 35:137
Alliger, R.J. 40:79
Alper, K.R. 35:95
Alvir, J.M.A. 35:1
Andreasen, N.C. 40:79, 40:157
Angrist, B. 40:11
Arató, M. 40:91
Arndt, S. 40:79, 40:157
Ashtari, M. 35:1, 40:203
Barocka, A. 40:247
Barouche, F. 40:11
Bartlett, E.J. 40:11, 40:115
Bartzokis, G. 40:239
Baxter, L.R., Jr. 40:195
Beiser, M. 40:21
Berent, S. 35:49
Betley, A.T. 35:49
Biedermann, J. 40:31
Bilder, R.M. 35:1
Blazer, D.G. 40:211
Bogerts, B. 35:1, 40:49, 40:203
Boivin, M.J. 35:49
Boyko, O.B. 40:95
Brodie, J.D. 40:11, 40:115
Brown, G.M. 40:135
Burr, G. 35:39
Camargo, E.E. 40:167
Cantor-Graae, E. 40:253
Casanova, M.F. 35:149
Chabot, R.J. 35:95
Christman, D. 35:39
Cleghorn, J.M. 40:135
Cohen, G.A. 40:79, 40:157
Colter, N. 35:137
Crocq, M.-A. 35:107
Crow, T.J. 35:137
Dauphinain, I.D. 35:137
Degreef, G. 35:1, 40:203
DeLisi, L.E. 35:137
Dewey, S.L. 35:39
Dierks, T. 40:181
Doraiswamy, P.M. 40:95, 40:211
Douglass, A. 40:1
Durst, P. 35:107
Ebert, D. 40:247
Escalona, P.R. 40:95
Feistel, H. 40:247
Figiel, G.S. 40:95
Flekköy, K. 35:27
Fowler, J.S. 35:39
Franco, S. 40:135
Franzén, G. 35:27, 40:253
Fröhlich, L. 40:181
Garber, H.J. 40:239
Garcia-Rill, E. 40:31
Garnett, E.S. 40:135
Gershon, E.S. 35:137
Gescuk, B. 40:1
Gillespie, H. 40:69
Giordani, B. 35:49
Grady, C.L. 40:221
Grant, C. 40:69
Griswold, V.J. 40:239
Gustafson, L. 35:27
Guze, B.H. 40:195
Harris, G.J. 40:61, 40:167
Harvey, I. 35:61
Hichwa, R.D. 35:49
Hirschowitz, J. 35:39
Hitzenmann, R. 35:39
Hollister, L. 40:69
Horwitz, B. 40:221
Husain, M.M. 40:31, 40:95
Iacono, W.G. 40:21
Ihl, R. 40:181
Ingvar, D.H. 40:253
Ivanovic, M. 40:69
Jernigan, T.L. 35:115
John, E.R. 35:95
Joseph, K.C. 35:91
Kaplan, R.D. 40:135
Karlon, S. 35:27
Karson, C.N. 40:31
Kim, A.H. 35:95
Kleinman, J.E. 35:149
Koepppe, R.A. 35:49
Krishnan, K.R.R. 40:95, 40:211
Kuhl, D.E. 35:49
Laska, E.M. 40:115
Lieberman, J.A. 35:1, 40:203
Lim, K.O. 35:15, 35:71
Links, J.M. 40:167
Logan, J. 35:39
MacCrimmon, D.J. 40:91
Macher, J.-P. 107
Marder, S.R. 40:239
Matthew, R.J. 40:125
Maurer, K. 40:181
Mazziotta, J.C. 40:195
McDonald, W.M. 40:95, 40:211
McGuffin, P. 35:61
McLaughlin, J.A. 40:49

- Mintz, J. 40:239
Mion, C.C. 40:157
Mitra, T. 40:49
Modell, J.G. 35:49
Mokrani, M.-C. 35:107
Mrak, R.E. 40:31
Mullan, N. 40:69
Murphy, G.M., Jr. 35:15
Na, C. 40:95
Nahmias, C. 40:135
Nasrallah, H.A. 40:49
Nemeroff, C.B. 40:95
Nilsson, A. 35:27
Noga, T. 40:61
Oldendorf, W.H. 40:239
Olson, S.C. 40:49
Pearlson, G.D. 40:61, 40:167
Perisic, I. 40:181
Pfefferbaum, A. 35:15, 35:71, 35:115
Phelps, M.E. 40:195
Pietrini, P. 40:221
Prichet, L.S. 35:95
Rapoport, J.L. 40:221
Rapoport, S.I. 40:221
Rhew, E.H. 40:61
Risberg, J. 35:27, 40:253
Rodriguez, G. 35:27
Rosenbloom, M.J. 35:115
Rothley, J.M. 35:49
Rotrosen, J. 40:11
Sanfilipo, M. 40:115
Schapiro, M.B. 40:221
Schlyer, D. 35:39
Schuff, N. 35:107
Schwartz, J.M. 40:195
Schwarzkopf, S.B. 40:49
Sitaram, N. 35:91
Skinner, R.D. 40:31
Sponheim, S.R. 40:21
Stevens, J.R. 35:149
Sullivan, E.V. 35:115
Swayze, V.W. II 40:79, 40:157
Swedo, S.E. 40:221
Szechtmann, B. 40:135
Szechtmann, H. 40:135
Szuba, M.P. 40:195
Szymanski, S. 40:203
Tancredi, 40:69
Tinklenberg, J.R. 35:115
Toone, B.K. 35:61
Tuma, I. 35:137
Vitkun, S. 35:39
Volkow, N.D. 35:39, 40:69
Warkentin, S. 35:27, 40:253
Wiesel, F.-A. 40:101
Wik, G. 40:101
Williams, W. 35:61
Wilson, W.H. 40:125
Wolf, A.P. 35:39, 40:11, 40:115
Wolkin, A. 40:11, 40:115
Woods, B.T. 40:1
Yesavage, J.A. 35:115
Zipursky, R.B. 35:15, 35:71, 35:115
Zito, J. 40:203

Subject Index for 1990-91

Affective disorder

- aging, late onset, 40:211
aging, magnetic resonance imaging, 40:211
aging, mania, 40:211
aging, subcortical hyperintensities, 40:211
Alzheimer's disease, frontal lobe, 40:195
Alzheimer's disease, glucose metabolism, 40:195
Alzheimer's disease, hippocampus, 40:195
Alzheimer's disease, positron emission tomography, 40:195
basal ganglia, limbic system, 40:95
basal ganglia, magnetic resonance imaging, 40:95
basal ganglia, putamen, 40:95
electroencephalographic topography, serotonin, 40:91
frontal lobe, Alzheimer's disease, 40:195
frontal lobe, glucose metabolism, 40:195
frontal lobe, hexamethylpropylene-amineoxime (HMPAO), 40:247
frontal lobe, hippocampus, 40:195
frontal lobe, limbic system, 40:247
frontal lobe, positron emission tomography, 40:195
frontal lobe, single photon emission computed tomography, 40:247
frontal lobe, sleep deprivation, 40:247
glucose metabolism, Alzheimer's disease, 40:195
glucose metabolism, frontal lobe, 40:195
glucose metabolism, hippocampus, 40:195
glucose metabolism, positron emission tomography, 40:195
hexamethylpropyleneamineoxime (HMPAO), frontal lobe, 40:247
hexamethylpropyleneamineoxime (HMPAO), limbic system, 40:247
hexamethylpropyleneamineoxime (HMPAO), single photon emission computed tomography, 40:247
hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
hippocampus, Alzheimer's disease, 40:195
hippocampus, frontal lobe, 40:195
hippocampus, glucose metabolism, 40:195
hippocampus, positron emission tomography, 40:195
late onset, aging, 40:211
late onset, magnetic resonance imaging, 40:211
late onset, mania, 40:211

Affective disorder continued

- late onset, subcortical hyperintensities, 40:211
limbic system, basal ganglia, 40:95
limbic system, hexamethylpropylene-amineoxime (HMPAO), 40:247
limbic system, magnetic resonance imaging, 40:95
limbic system, putamen, 40:95
limbic system, single photon emission computed tomography, 40:247
limbic system, sleep deprivation, 40:247
magnetic resonance imaging, aging, 40:211
magnetic resonance imaging, basal ganglia, 40:95
magnetic resonance imaging, late onset, 40:211
magnetic resonance imaging, limbic system, 40:95
magnetic resonance imaging, mania, 40:211
magnetic resonance imaging, putamen, 40:95
magnetic resonance imaging, subcortical hyperintensities, 40:211
mania, aging, 40:211
mania, late onset, 40:211
mania, magnetic resonance imaging, 40:211
mania, subcortical hyperintensities, 40:211
positron emission tomography, Alzheimer's disease, 40:195
positron emission tomography, frontal lobe, 40:195
positron emission tomography, glucose metabolism, 40:195
positron emission tomography, hippocampus, 40:195
putamen, basal ganglia, 40:95
putamen, limbic system, 40:95
putamen, magnetic resonance imaging, 40:95
serotonin, electroencephalographic topography, 40:91
sleep, frontal lobe, 40:247
sleep, hexamethylpropyleneamineoxime (HMPAO), 40:247
sleep, limbic system, 40:247
sleep, single photon emission computed tomography, 40:247
sleep deprivation, frontal lobe, 40:247
sleep deprivation, hexamethylpropylene-amineoxime (HMPAO), 40:247
sleep deprivation, limbic system, 40:247
sleep deprivation, single photon emission computed tomography, 40:247

- Affective disorder** continued
 single photon emission computed tomography, frontal lobe, 40:247
 single photon emission computed tomography, hexamethylpropylene-amineoxime (HMPAO), 40:247
 single photon emission computed tomography, limbic system, 40:247
 single photon emission computed tomography, sleep deprivation, 40:247
 subcortical hyperintensities, aging, 40:211
 subcortical hyperintensities, late onset, 40:211
 subcortical hyperintensities, magnetic resonance imaging, 40:211
 subcortical hyperintensities, mania, 40:211
- Aging**
 affective disorder, late onset, 40:211
 affective disorder, magnetic resonance imaging, 40:211
 affective disorder, mania, 40:211
 affective disorder, subcortical hyperintensities, 40:211
 Alzheimer's disease, cognition, 35:115
 Alzheimer's disease, computed tomography, 35:115
 Alzheimer's disease, Mini-Mental State Examination, 35:115
 Alzheimer's disease, ventricular size, 35:115
 Alzheimer's disease, Wechsler Adult Intelligence Scale, 35:115
 brain size, magnetic resonance imaging, 40:61
 cognition, Alzheimer's disease, 35:115
 cognition, computed tomography, 35:115
 cognition, Mini-Mental State Examination, 35:115
 cognition, ventricular size, 35:115
 cognition, Wechsler Adult Intelligence Scale, 35:115
 computed tomography, Alzheimer's disease, 35:115
 computed tomography, cognition, 35:115
 computed tomography, Mini-Mental State Examination, 35:115
 computed tomography, ventricular size, 35:115
 computed tomography, Wechsler Adult Intelligence Scale, 35:115
 hippocampus, magnetic resonance imaging, 35:15
 hippocampus, ventricular size, 35:15
 late onset, affective disorder, 40:211
 late onset, magnetic resonance imaging, 40:211
- Aging** continued
 late onset, mania, 40:211
 late onset, subcortical hyperintensities, 40:211
 limbic system, magnetic resonance imaging, 35:15
 limbic system, ventricular size, 35:15
 magnetic resonance imaging, affective disorder, 40:211
 magnetic resonance imaging, brain size, 40:61
 magnetic resonance imaging, hippocampus, 35:15
 magnetic resonance imaging, late onset, 40:211
 magnetic resonance imaging, limbic system, 35:15
 magnetic resonance imaging, mania, 40:211
 magnetic resonance imaging, subcortical hyperintensities, 40:211
 magnetic resonance imaging, ventricular size, 35:15
 mania, affective disorder, 40:211
 mania, late onset, 40:211
 mania, magnetic resonance imaging, 40:211
 mania, subcortical hyperintensities, 40:211
 Mini-Mental State Examination, Alzheimer's disease, 35:115
 Mini-Mental State Examination, cognition, 35:115
 Mini-Mental State Examination, computed tomography, 35:115
 Mini-Mental State Examination, ventricular size, 35:115
 subcortical hyperintensities, affective disorder, 40:211
 subcortical hyperintensities, late onset, 40:211
 subcortical hyperintensities, magnetic resonance imaging, 40:211
 subcortical hyperintensities, mania, 40:211
 ventricular size, Alzheimer's disease, 35:115
 ventricular size, cognition, 35:115
 ventricular size, computed tomography, 35:115
 ventricular size, hippocampus, 35:15
 ventricular size, limbic system, 35:15
 ventricular size, magnetic resonance imaging, 35:15
 ventricular size, Mini-Mental State Examination, 35:115
 ventricular size, Wechsler Adult Intelligence Scale, 35:115
 Wechsler Adult Intelligence Scale, Alzheimer's disease, 35:115

- Aging** continued
 Wechsler Adult Intelligence Scale, cognition, 35:115
 Wechsler Adult Intelligence Scale, computed tomography, 35:115
 Wechsler Adult Intelligence Scale, ventricular size, 35:115
Alcohol. See Ethanol
Alcoholism
 computed tomography, measurement reliability, 40:1
 measurement reliability, computed tomography, 40:1
 ventricle-brain ratio, computed tomography, 40:1
Alzheimer's disease
 affective disorder, frontal lobe, 40:195
 affective disorder, glucose metabolism, 40:195
 affective disorder, hippocampus, 40:195
 affective disorder, positron emission tomography, 40:195
 aging, cognition, 35:115
 aging, computed tomography, 35:115
 aging, Mini-Mental State Examination, 35:115
 aging, ventricular size, 35:115
 aging, Wechsler Adult Intelligence Scale, 35:115
 astrocytosis, dentate gyrus, 35:149
 astrocytosis, entorhinal cortex, 35:149
 astrocytosis, hippocampus, 35:149
 astrocytosis, post-mortem examination, 35:149
 astrocytosis, schizophrenia, 35:149
 blood flow, cortical circumferential analysis, 40:167
 blood flow, iodoamphetamine, 40:167
 blood flow, single photon emission computed tomography, 40:167
 brain size, magnetic resonance imaging, 40:61
 cognition, aging, 35:115
 cognition, computed tomography, 35:115
 cognition, Mini-Mental State Examination, 35:115
 cognition, ventricular size, 35:115
 cognition, Wechsler Adult Intelligence Scale, 35:115
 computed tomography, aging, 35:115
 computed tomography, cognition, 35:115
 computed tomography, Mini-Mental State Examination, 35:115
 computed tomography, neuropsychology, 35:115
- Alzheimer's disease** continued
 computed tomography, ventricular size, 35:115
 computed tomography, Wechsler Adult Intelligence Scale, 35:115
 cortical circumferential analysis, blood flow, 40:167
 cortical circumferential analysis, iodoamphetamine, 40:167
 cortical circumferential analysis, single photon emission computed tomography, 40:167
 dentate gyrus, astrocytosis, 35:149
 dentate gyrus, entorhinal cortex, 35:149
 dentate gyrus, hippocampus, 35:149
 dentate gyrus, post-mortem examination, 35:149
 dentate gyrus, schizophrenia, 35:149
 electroencephalographic topography, neuropsychology, 40:181
 electroencephalographic topography, severity of dementia, 40:181
 entorhinal cortex, astrocytosis, 35:149
 entorhinal cortex, dentate gyrus, 35:149
 entorhinal cortex, hippocampus, 35:149
 entorhinal cortex, post-mortem examination, 35:149
 entorhinal cortex, schizophrenia, 35:149
 frontal lobe, affective disorder, 40:195
 frontal lobe, glucose metabolism, 40:195
 frontal lobe, hippocampus, 40:195
 frontal lobe, positron emission tomography, 40:195
 glucose metabolism, affective disorder, 40:195
 glucose metabolism, frontal lobe, 40:195
 glucose metabolism, hippocampus, 40:195
 glucose metabolism, positron emission tomography, 40:195
 hippocampus, affective disorder, 40:195
 hippocampus, astrocytosis, 35:149
 hippocampus, dentate gyrus, 35:149
 hippocampus, entorhinal cortex, 35:149
 hippocampus, frontal lobe, 40:195
 hippocampus, glucose metabolism, 40:195
 hippocampus, positron emission tomography, 40:195
 hippocampus, post-mortem examination, 35:149
 hippocampus, schizophrenia, 35:149
 iodoamphetamine, blood flow, 40:167
 iodoamphetamine, cortical circumferential analysis, 40:167
 iodoamphetamine, single photon emission computed tomography, 40:167

- Alzheimer's disease** continued
 magnetic resonance imaging, brain size, 40:61
Mini-Mental State Examination, aging, 35:115
Mini-Mental State Examination, cognition, 35:115
Mini-Mental State Examination, computed tomography, 35:115
Mini-Mental State Examination, ventricular size, 35:115
Mini-Mental State Examination, Wechsler Adult Intelligence Scale, 35:115
 neuropsychology, computed tomography, 35:115
 neuropsychology, electroencephalographic topography, 40:181
 neuropsychology, severity of dementia, 40:181
 positron emission tomography, affective disorder, 40:195
 positron emission tomography, frontal lobe, 40:195
 positron emission tomography, glucose metabolism, 40:195
 positron emission tomography, hippocampus, 40:195
 post-mortem examination, astrocytosis, 35:149
 post-mortem examination, dentate gyrus, 35:149
 post-mortem examination, entorhinal cortex, 35:149
 post-mortem examination, hippocampus, 35:149
 post-mortem examination, schizophrenia, 35:149
 schizophrenia, astrocytosis, 35:149
 schizophrenia, dentate gyrus, 35:149
 schizophrenia, entorhinal cortex, 35:149
 schizophrenia, hippocampus, 35:149
 schizophrenia, post-mortem examination, 35:149
 severity of dementia, electroencephalographic topography, 40:181
 severity of dementia, neuropsychology, 40:181
 single photon emission computed tomography, blood flow, 40:167
 single photon emission computed tomography, cortical circumferential analysis, 40:167
 single photon emission computed tomography, iodoamphetamine, 40:167
- Alzheimer's disease** continued
 ventricular size, aging, 35:115
 ventricular size, cognition, 35:115
 ventricular size, computed tomography, 35:115
 ventricular size, Mini-Mental State Examination, 35:115
 ventricular size, Wechsler Adult Intelligence Scale, 35:115
 Wechsler Adult Intelligence Scale, aging, 35:115
 Wechsler Adult Intelligence Scale, cognition, 35:115
 Wechsler Adult Intelligence Scale, computed tomography, 35:115
 Wechsler Adult Intelligence Scale, Mini-Mental State Examination, 35:115
 Wechsler Adult Intelligence Scale, ventricular size, 35:115
- Amygdala**
 genetics, hippocampus, 35:137
 genetics, magnetic resonance imaging, 35:137
 genetics, schizophrenia, 35:137
 genetics, temporal lobe, 35:137
 genetics, ventricular size, 35:137
 hippocampus, genetics, 35:137
 hippocampus, magnetic resonance imaging, 35:1, 35:137
 hippocampus, schizophrenia, 35:1, 35:137
 hippocampus, temporal horn volume, 35:1
 hippocampus, temporal lobe, 35:1, 35:137
 hippocampus, ventricular size, 35:137
 magnetic resonance imaging, genetics, 35:137
 magnetic resonance imaging, hippocampus, 35:1, 35:137
 magnetic resonance imaging, schizophrenia, 35:1, 35:137
 magnetic resonance imaging, temporal horn volume, 35:1
 magnetic resonance imaging, temporal lobe, 35:1, 35:137
 magnetic resonance imaging, ventricular size, 35:137
 schizophrenia, genetics, 35:137
 schizophrenia, hippocampus, 35:1, 35:137
 schizophrenia, magnetic resonance imaging, 35:1, 35:137
 schizophrenia, temporal horn volume, 35:1
 schizophrenia, temporal lobe, 35:1, 35:137
 schizophrenia, ventricular size, 35:137
 temporal horn volume, hippocampus, 35:1
 temporal horn volume, magnetic resonance imaging, 35:1

Amygdala continued

temporal horn volume, schizophrenia, 35:1
 temporal lobe, genetics, 35:137
 temporal lobe, hippocampus, 35:1, 35:137
 temporal lobe, magnetic resonance imaging, 35:1, 35:137
 temporal lobe, schizophrenia, 35:1, 35:137
 temporal lobe, ventricular size, 35:137
 ventricular size, genetics, 35:137
 ventricular size, hippocampus, 35:137
 ventricular size, magnetic resonance imaging, 35:137
 ventricular size, schizophrenia, 35:137
 ventricular size, temporal lobe, 35:137

Anxiety
 blood flow, diazepam, 40:125
 blood flow, generalized anxiety disorder, 40:125
 blood flow, ondansetron, 40:125
 diazepam, blood flow, 40:125
 diazepam, generalized anxiety disorder, 40:125
 diazepam, ondansetron, 40:125
 frontal lobe, glucose metabolism, 35:49
 40:101
 frontal lobe, homovanillic acid, 40:101
 frontal lobe, laterality, 35:49
 frontal lobe, positron emission tomography, 35:49, 40:101
 frontal lobe, prolactin, 40:101
 frontal lobe, schizophrenia, 40:101
 frontal lobe, State-Trait Anxiety Inventory, 35:49
 generalized anxiety disorder, blood flow, 40:125
 generalized anxiety disorder, diazepam, 40:125
 generalized anxiety disorder, ondansetron, 40:125
 glucose metabolism, frontal lobe, 35:49, 40:101
 glucose metabolism, homovanillic acid, 40:101
 glucose metabolism, laterality, 35:49
 glucose metabolism, positron emission tomography, 35:49, 40:101
 glucose metabolism, prolactin, 40:101
 glucose metabolism, schizophrenia, 40:101
 glucose metabolism, State-Trait Anxiety Inventory, 35:49
 homovanillic acid, frontal lobe, 40:101
 homovanillic acid, glucose metabolism, 40:101
 homovanillic acid, positron emission tomography, 40:101

Anxiety continued

homovanillic acid, prolactin, 40:101
 homovanillic acid, schizophrenia, 40:101
 laterality, frontal lobe, 35:49
 laterality, glucose metabolism, 35:49
 laterality, positron emission tomography, 35:49
 laterality, State-Trait Anxiety Inventory, 35:49
 ondansetron, blood flow, 40:125
 ondansetron, diazepam, 40:125
 ondansetron, generalized anxiety disorder, 40:125
 positron emission tomography, frontal lobe, 35:49, 40:101
 positron emission tomography, glucose metabolism, 35:49, 40:101
 positron emission tomography, homovanillic acid, 40:101
 positron emission tomography, laterality, 35:49
 positron emission tomography, prolactin, 40:101
 positron emission tomography, schizophrenia, 40:101
 positron emission tomography, State-Trait Anxiety Inventory, 35:49
 prolactin, frontal lobe, 40:101
 prolactin, glucose metabolism, 40:101
 prolactin, homovanillic acid, 40:101
 prolactin, positron emission tomography, 40:101
 prolactin, schizophrenia, 40:101
 schizophrenia, frontal lobe, 40:101
 schizophrenia, glucose metabolism, 40:101
 schizophrenia, homovanillic acid, 40:101
 schizophrenia, positron emission tomography, 40:101
 schizophrenia, prolactin, 40:101
 State-Trait Anxiety Inventory, frontal lobe, 35:49
 State-Trait Anxiety Inventory, glucose metabolism, 35:49
 State-Trait Anxiety Inventory, laterality, 35:49
 State-Trait Anxiety Inventory, positron emission tomography, 35:49
Apomorphine
 frontal lobe, glucose metabolism, 40:135
 frontal lobe, never-medicated patients, 40:135
 frontal lobe, positron emission tomography, 40:135
 frontal lobe, schizophrenia, 40:135

- Apomorphine** continued
 frontal lobe, temporal lobe, 40:135
 glucose metabolism, frontal lobe, 40:135
 glucose metabolism, never-medicated patients, 40:135
 glucose metabolism, positron emission tomography, 40:135
 glucose metabolism, schizophrenia, 40:135
 glucose metabolism, temporal lobe, 40:135
 never-medicated patients, frontal lobe, 40:135
 never-medicated patients, glucose metabolism, 40:135
 never-medicated patients, positron emission tomography, 40:135
 never-medicated patients, schizophrenia, 40:135
 never-medicated patients, temporal lobe, 40:135
 positron emission tomography, frontal lobe, 40:135
 positron emission tomography, glucose metabolism, 40:135
 positron emission tomography, never-medicated patients, 40:135
 positron emission tomography, schizophrenia, 40:135
 positron emission tomography, temporal lobe, 40:135
 schizophrenia, frontal lobe, 40:135
 schizophrenia, glucose metabolism, 40:135
 schizophrenia, never-medicated patients, 40:135
 schizophrenia, positron emission tomography, 40:135
 schizophrenia, temporal lobe, 40:135
 temporal lobe, frontal lobe, 40:135
 temporal lobe, glucose metabolism, 40:135
 temporal lobe, never-medicated patients, 40:135
 temporal lobe, positron emission tomography, 40:135
 temporal lobe, schizophrenia, 40:135
Arecoline
 electroencephalographic topography, polysomnography, 35:91
 electroencephalographic topography, sleep, 35:91
 polysomnography, electroencephalographic topography, 35:91
 sleep, electroencephalographic topography, 35:91
Basal ganglia
 affective disorder, limbic system, 40:95
Basal ganglia continued
 affective disorder, magnetic resonance imaging, 40:95
 affective disorder, putamen, 40:95
 frontal lobe, glucose, 40:115
 frontal lobe, neuroleptics, 40:115
 frontal lobe, positron emission tomography, 40:115
 frontal lobe, schizophrenia, 40:115
 glucose, frontal lobe, 40:115
 glucose, neuroleptics, 40:115
 glucose, positron emission tomography, 40:115
 glucose, schizophrenia, 40:115
 limbic system, affective disorder, 40:95
 limbic system, magnetic resonance imaging, 40:95
 limbic system, putamen, 40:95
 magnetic resonance imaging, affective disorder, 40:95
 magnetic resonance imaging, limbic system, 40:95
 magnetic resonance imaging, putamen, 40:95
 magnetic resonance imaging, schizophrenia, 40:157
 magnetic resonance imaging, tardive dyskinesia, 40:157
 neuroleptics, frontal lobe, 40:115
 neuroleptics, glucose, 40:115
 neuroleptics, positron emission tomography, 40:115
 neuroleptics, schizophrenia, 40:115
 positron emission tomography, frontal lobe, 40:115
 positron emission tomography, glucose, 40:115
 positron emission tomography, neuroleptics, 40:115
 positron emission tomography, schizophrenia, 40:115
 putamen, affective disorder, 40:95
 putamen, limbic system, 40:95
 putamen, magnetic resonance imaging, 40:95
 schizophrenia, frontal lobe, 40:115
 schizophrenia, glucose, 40:115
 schizophrenia, magnetic resonance imaging, 40:157
 schizophrenia, neuroleptics, 40:115
 schizophrenia, positron emission tomography, 40:115
 schizophrenia, tardive dyskinesia, 40:157
 tardive dyskinesia, magnetic resonance imaging, 40:157
 tardive dyskinesia, schizophrenia, 40:157

Benzodiazepine. See *Diazepam***Blood flow**

- Alzheimer's disease, cortical circumferential analysis, 40:167
 Alzheimer's disease, iodoamphetamine, 40:167
 Alzheimer's disease, single photon emission computed tomography, 40:167
 anxiety, diazepam, 40:125
 anxiety, ondansetron, 40:125
 Chicago Word Fluency Test, neuropsychology, 40:253
 cortical circumferential analysis, Alzheimer's disease, 40:167
 cortical circumferential analysis, iodoamphetamine, 40:167
 cortical circumferential analysis, single photon emission computed tomography, 40:167
 diazepam, anxiety, 40:125
 diazepam, generalized anxiety disorder, 40:125
 diazepam, ondansetron, 40:125
 frontal lobe, long-term followup, 40:253
 frontal lobe, schizophrenia, 35:27, 40:253
 frontal lobe, symptom severity, 35:27
 generalized anxiety disorder, diazepam, 40:125
 generalized anxiety disorder, ondansetron, 40:125
 iodoamphetamine, Alzheimer's disease, 40:167
 iodoamphetamine, cortical circumferential analysis, 40:167
 iodoamphetamine, single photon emission computed tomography, 40:167
 long-term followup, frontal lobe, 40:253
 long-term followup, schizophrenia, 40:253
 neuropsychology, Chicago Word Fluency Test, 40:253
 neuropsychology, schizophrenia, 40:253
 neuropsychology, Wisconsin Card Sort Test, 40:253
 ondansetron, anxiety, 40:125
 ondansetron, diazepam, 40:125
 ondansetron, generalized anxiety disorder, 40:125
 schizophrenia, frontal lobe, 35:27, 40:253
 schizophrenia, long-term followup, 40:253
 schizophrenia, neuropsychology, 40:253
 schizophrenia, symptom severity, 35:27
 schizophrenia, Wisconsin Card Sort Test, 40:253
 single photon emission computed tomography, Alzheimer's disease, 40:167
 single photon emission computed tomography, cortical circumferential analysis, 40:167

Blood flow continued

- single photon emission computed tomography, iodoamphetamine, 40:167
 symptom severity, frontal lobe, 35:27
 symptom severity, schizophrenia, 35:27
 Wisconsin Card Sort Test, neuropsychology, 40:253
 Wisconsin Card Sort Test, schizophrenia, 40:253
Brain electrical activity mapping. See *electroencephalographic topography*
Brain stem
 locus ceruleus, neuropathology, 40:31
 locus ceruleus, nicotinamide adenosine dinucleotide phosphate, 40:31
 locus ceruleus, pedunculopontine nucleus, 40:31
 locus ceruleus, schizophrenia, 40:31
 neuropathology, locus ceruleus, 40:31
 neuropathology, nicotinamide adenosine dinucleotide phosphate, 40:31
 neuropathology, pedunculopontine nucleus, 40:31
 neuropathology, schizophrenia, 40:31
 nicotinamide adenosine dinucleotide phosphate, locus ceruleus, 40:31
 nicotinamide adenosine dinucleotide phosphate, neuropathology, 40:31
 nicotinamide adenosine dinucleotide phosphate, pedunculopontine nucleus, 40:31
 nicotinamide adenosine dinucleotide phosphate, schizophrinia, 40:31
 pedunculopontine nucleus, locus ceruleus, 40:31
 pedunculopontine nucleus, nicotinamide adenosine dinucleotide phosphate, 40:31
 pedunculopontine nucleus, neuropathology, 40:31
 pedunculopontine nucleus, schizophrenia, 40:31
 schizophrinia, locus ceruleus, 40:31
 schizophrinia, nicotinamide adenosine dinucleotide phosphate, 40:31
 schizophrinia, neuropathology, 40:31
 schizophrinia, pedunculopontine nucleus, 40:31
Brain volume
 computer methods, magnetic resonance imaging, 40:61
 magnetic resonance imaging, computer methods, 40:61
Cerebral blood flow. See *Blood flow*
Clomipramine
 electroencephalographic topography, evoked potentials, 40:91
 electroencephalographic topography, fluoxetine, 40:91

- Clomipramine** continued
 electroencephalographic topography,
 laterality, 40:91
 electroencephalographic topography, P300,
 40:91
 electroencephalographic topography,
 serotonin, 40:91
 evoked potentials, electroencephalographic
 topography, 40:91
 evoked potentials, fluoxetine, 40:91
 evoked potentials, laterality, 40:91
 evoked potentials, P300, 40:91
 evoked potentials, serotonin, 40:91
 fluoxetine, electroencephalographic
 topography, 40:91
 fluoxetine, evoked potentials, 40:91
 fluoxetine, laterality, 40:91
 fluoxetine, P300, 40:91
 fluoxetine, serotonin, 40:91
 laterality, electroencephalographic
 topography, 40:91
 laterality, evoked potentials, 40:91
 laterality, fluoxetine, 40:91
 laterality, P300, 40:91
 laterality, serotonin, 40:91
 P300, electroencephalographic topography,
 40:91
 P300, evoked potentials, 40:91
 P300, fluoxetine, 40:91
 P300, laterality, 40:91
 P300, serotonin, 40:91
 serotonin, electroencephalographic
 topography, 40:91
 serotonin, evoked potentials, 40:91
 serotonin, fluoxetine, 40:91
 serotonin, laterality, 40:91
 serotonin, P300, 40:91
- Cocaine**
 alpha power, Beck Depression Scale, 35:95
 alpha power, electroencephalographic
 topography, 35:95
 alpha power, substance abuse, 35:95
 Beck Depression Scale, alpha power, 35:95
 Beck Depression Scale,
 electroencephalographic topography,
 35:95
 Beck Depression Scale, substance abuse,
 35:95
 electroencephalographic topography, alpha
 power, 35:95
 electroencephalographic topography, Beck
 Depression Scale, 35:95
 electroencephalographic topography,
 substance abuse, 35:95
- Cocaine** continued
 substance abuse, alpha power, 35:95
 substance abuse, Beck Depression Scale,
 35:95
 substance abuse, electroencephalographic
 topography, 35:95
Cognition
 Alzheimer's disease, Brief Cognitive Rating
 Scale, 40:181
 Alzheimer's disease, electroencephalographic
 topography, 40:181
 Brief Cognitive Rating Scale, Alzheimer's
 disease, 40:181
 Brief Cognitive Rating Scale,
 electroencephalographic topography,
 40:181
 electroencephalographic topography,
 Alzheimer's disease, 40:181
 electroencephalographic topography, Brief
 Cognitive Rating Scale, 40:181
Computed tomography
 admixture analysis, genetics, 35:61
 admixture analysis, schizophrenia, 35:61
 admixture analysis, ventricle-brain ratio,
 35:61
 aging, Alzheimer's disease, 35:115
 aging, cognition, 35:115
 aging, Mini-Mental State Examination,
 35:115
 aging, ventricular size, 35:115
 aging, Wechsler Adult Intelligence Scale,
 35:115
 alcoholism, measurement reliability, 40:1
 alcoholism, ventricle-brain ratio, 40:1
 Alzheimer's disease, aging, 35:115
 Alzheimer's disease, cognition, 35:115
 Alzheimer's disease, Mini-Mental State
 Examination, 35:115
 Alzheimer's disease, neuropsychology,
 35:115
 Alzheimer's disease, ventricular size, 35:115
 Alzheimer's disease, Wechsler Adult
 Intelligence Scale, 35:115
 cerebral asymmetry, laterality, 35:71
 cerebral asymmetry, measurement methods,
 35:71
 cognition, aging, 35:115
 cognition, Alzheimer's disease, 35:115
 cognition, Mini-Mental State Examination,
 35:115
 cognition, ventricular size, 35:115
 cognition, Wechsler Adult Intelligence
 Scale, 35:115
 genetics, admixture analysis, 35:61

Computed tomography continued
 genetics, schizophrenia, 35:61
 genetics, ventricle-brain ratio, 35:61
 laterality, cerebral asymmetry, 35:71
 laterality, measurement methods, 35:71
 measurement methods, cerebral asymmetry, 35:71
 measurement methods, laterality, 35:71
 measurement reliability, alcoholism, 40:1
 measurement reliability, ventricle-brain ratio, 40:1
Mini-Mental State Examination, aging, 35:115
Mini-Mental State Examination, Alzheimer's disease, 35:115
Mini-Mental State Examination, cognition, 35:115
Mini-Mental State Examination, ventricular size, 35:115
Mini-Mental State Examination, Wechsler Adult Intelligence Scale, 35:115
 neuropsychology, Alzheimer's disease, 35:115
 occipital horn size, reliability, 40:21
 reliability, occipital horn size, 40:21
 schizophrenia, admixture analysis, 35:61
 schizophrenia, genetics, 35:61
 schizophrenia, stability after psychosis onset, 40:21
 schizophrenia, ventricle-brain ratio, 35:61
 schizophrenia, ventricular size, 40:21
 stability after psychosis onset, schizophrenia, 40:21
 stability after psychosis onset, ventricular size, 40:21
 ventricle-brain ratio, admixture analysis, 35:61
 ventricle-brain ratio, alcoholism, 40:1
 ventricle-brain ratio, genetics, 35:61
 ventricle-brain ratio, measurement reliability, 40:1
 ventricle-brain ratio, schizophrenia, 35:61
 ventricular size, aging, 35:115
 ventricular size, Alzheimer's disease, 35:115
 ventricular size, cognition, 35:115
 ventricular size, Mini-Mental State Examination, 35:115
 ventricular size, schizophrenia, 40:21
 ventricular size, stability after psychosis onset, 40:21
 ventricular size, Wechsler Adult Intelligence Scale, 35:115
Wechsler Adult Intelligence Scale, aging, 35:115

Computed tomography continued
Wechsler Adult Intelligence Scale, Alzheimer's disease, 35:115
Wechsler Adult Intelligence Scale, cognition, 35:115
Wechsler Adult Intelligence Scale, Mini-Mental State Examination, 35:115
Wechsler Adult Intelligence Scale, ventricular size, 35:115
Crack. See Cocaine
Depression. See Affective disorder
Diazepam
 anxiety, blood flow, 40:125
 anxiety, generalized anxiety disorder, 40:125
 anxiety, ondansetron, 40:125
 blood flow, anxiety, 40:125
 blood flow, generalized anxiety disorder, 40:125
 blood flow, ondansetron, 40:125
 generalized anxiety disorder, anxiety, 40:125
 generalized anxiety disorder, blood flow, 40:125
 generalized anxiety disorder, ondansetron, 40:125
 ondansetron, anxiety, 40:125
 ondansetron, blood flow, 40:125
 ondansetron, generalized anxiety disorder, 40:125
Dorsolateral prefrontal cortex. See Frontal lobe
Electroencephalographic topography
 affective disorder, serotonin, 40:91
 alpha power, Beck Depression Scale, 35:95
 alpha power, cocaine, 35:95
 alpha power, substance abuse, 35:95
 Alzheimer's disease, Brief Cognitive Rating Scale, 40:181
 Alzheimer's disease, cognition, 40:181
 Alzheimer's disease, neuropsychology, 40:181
 Alzheimer's disease, severity of dementia, 40:181
 arecoline, polysomnography, 35:91
 arecoline, sleep, 35:91
 Beck Depression Scale, alpha power, 35:95
 Beck Depression Scale, cocaine, 35:95
 Beck Depression Scale, substance abuse, 35:95
 Brief Cognitive Rating Scale, Alzheimer's disease, 40:181
 Brief Cognitive Rating Scale, cognition, 40:181
 clomipramine, evoked potentials, 40:91
 clomipramine, fluoxetine, 40:91

Electroencephalographic topography
 continued
 clomipramine, laterality, 40:91
 clomipramine, P300, 40:91
 clomipramine, serotonin, 40:91
 cocaine, alpha power, 35:95
 cocaine, Beck Depression Scale, 35:95
 cocaine, substance abuse, 35:95
 cognition, Alzheimer's disease, 40:181
 cognition, Brief Cognitive Rating Scale, 40:181
 evoked potentials, clomipramine, 40:91
 evoked potentials, fluoxetine, 40:91
 evoked potentials, laterality, 40:91
 evoked potentials, P300, 40:91
 evoked potentials, serotonin, 40:91
 fluoxetine, clomipramine, 40:91
 fluoxetine, evoked potentials, 40:91
 fluoxetine, laterality, 40:91
 fluoxetine, P300, 40:91
 fluoxetine, serotonin, 40:91
 laterality, clomipramine, 40:91
 laterality, evoked potentials, 40:91
 laterality, fluoxetine, 40:91
 laterality, P300, 40:91
 laterality, serotonin, 40:91
 neuropsychology, Alzheimer's disease, 40:181
 neuropsychology, severity of dementia, 40:181
 P300, clomipramine, 40:91
 P300, evoked potentials, 40:91
 P300, fluoxetine, 40:91
 P300, laterality, 40:91
 P300, serotonin, 40:91
 polysomnography, arecoline, 35:91
 serotonin, affective disorder, 40:91
 serotonin, clomipramine, 40:91
 serotonin, evoked potentials, 40:91
 serotonin, fluoxetine, 40:91
 serotonin, laterality, 40:91
 serotonin, P300, 40:91
 severity of dementia, Alzheimer's disease, 40:181
 severity of dementia, neuropsychology, 40:181
 sleep, arecoline, 35:91
 substance abuse, alpha power, 35:95
 substance abuse, Beck Depression Scale, 35:95
 substance abuse, cocaine, 35:95
Ethanol
 glucose metabolism, positron emission tomography, 35:39

Ethanol continued
 positron emission tomography, glucose metabolism, 35:39
Evoked potential
 clomipramine, electroencephalographic topography, 40:91
 clomipramine, fluoxetine, 40:91
 clomipramine, laterality, 40:91
 clomipramine, P300, 40:91
 clomipramine, serotonin, 40:91
 electroencephalographic topography, clomipramine, 40:91
 electroencephalographic topography, fluoxetine, 40:91
 electroencephalographic topography, laterality, 40:91
 electroencephalographic topography, P300, 40:91
 electroencephalographic topography, serotonin, 40:91
 fluoxetine, clomipramine, 40:91
 fluoxetine, electroencephalographic topography, 40:91
 fluoxetine, laterality, 40:91
 fluoxetine, P300, 40:91
 fluoxetine, serotonin, 40:91
 laterality, clomipramine, 40:91
 laterality, electroencephalographic topography, 40:91
 laterality, fluoxetine, 40:91
 laterality, P300, 40:91
 laterality, serotonin, 40:91
 P300, clomipramine, 40:91
 P300, electroencephalographic topography, 40:91
 P300, fluoxetine, 40:91
 P300, laterality, 40:91
 P300, serotonin, 40:91
 serotonin, clomipramine, 40:91
 serotonin, electroencephalographic topography, 40:91
 serotonin, fluoxetine, 40:91
 serotonin, laterality, 40:91
 serotonin, P300, 40:91
Fluoxetine
 clomipramine, electroencephalographic topography, 40:91
 clomipramine, evoked potentials, 40:91
 clomipramine, laterality, 40:91
 clomipramine, P300, 40:91
 clomipramine, serotonin, 40:91
 electroencephalographic topography, clomipramine, 40:91
 electroencephalographic topography, evoked

- Fluoxetine** continued
 potentials, 40:91
 electroencephalographic topography,
 laterality, 40:91
 electroencephalographic topography, P300,
 40:91
 electroencephalographic topography,
 serotonin, 40:91
 evoked potentials, clomipramine, 40:91
 evoked potentials, electroencephalographic
 topography, 40:91
 evoked potentials, laterality, 40:91
 evoked potentials, P300, 40:91
 evoked potentials, serotonin, 40:91
 laterality, clomipramine, 40:91
 laterality, electroencephalographic
 topography, 40:91
 laterality, evoked potentials, 40:91
 laterality, P300, 40:91
 laterality, serotonin, 40:91
 P300, clomipramine, 40:91
 P300, electroencephalographic topography,
 40:91
 P300, evoked potentials, 40:91
 P300, laterality, 40:91
 P300, serotonin, 40:91
 serotonin, clomipramine, 40:91
 serotonin, electroencephalographic
 topography, 40:91
 serotonin, evoked potentials, 40:91
 serotonin, laterality, 40:91
 serotonin, P300, 40:91
Fluphenazine
 magnetic resonance spectroscopy,
 pharmacokinetics, 35:107
 magnetic resonance spectroscopy,
 schizophrenia, 35:107
 pharmacokinetics, magnetic resonance
 spectroscopy, 35:107
 pharmacokinetics, schizophrenia, 35:107
 schizophrenia, magnetic resonance
 spectroscopy, 35:107
 schizophrenia, pharmacokinetics, 35:107
Frontal lobe
 affective disorder, Alzheimer's disease,
 40:195
 affective disorder, glucose metabolism,
 40:195
 affective disorder, hexamethylpropylene-
 amineoxime (HMPAO), 40:247
 affective disorder, hippocampus, 40:195
 affective disorder, limbic system, 40:247
 affective disorder, positron emission
 tomography, 40:195
Frontal lobe continued
 affective disorder, sleep, 40:247
 affective disorder, sleep deprivation, 40:247
 affective disorder, single photon emission
 computed tomography, 40:247
 Alzheimer's disease, affective disorder,
 40:195
 Alzheimer's disease, glucose metabolism,
 40:195
 Alzheimer's disease, hippocampus, 40:195
 Alzheimer's disease, positron emission
 tomography, 40:195
 anxiety, glucose metabolism, 35:49, 40:101
 anxiety, homovanillic acid, 40:101
 anxiety, laterality, 35:49
 anxiety, positron emission tomography,
 35:49, 40:101
 anxiety, prolactin, 40:101
 anxiety, schizophrenia, 40:101
 anxiety, State-Trait Anxiety Inventory,
 35:49
 apomorphine, glucose metabolism, 40:135
 apomorphine, never-medicated patients,
 40:135
 apomorphine, positron emission
 tomography, 40:135
 apomorphine, schizophrenia, 40:135
 apomorphine, temporal lobe, 40:135
 basal ganglia, glucose, 40:115
 basal ganglia, neuroleptics, 40:115
 basal ganglia, positron emission
 tomography, 40:115
 basal ganglia, schizophrenia, 40:115
 blood flow, long-term followup, 40:253
 blood flow, schizophrenia, 35:27, 40:253
 blood flow, symptom severity, 35:27
 correlation analysis, glucose metabolism,
 40:221
 correlation analysis, limbic system, 40:221
 correlation analysis, obsessive-compulsive
 disorder, 40:221
 correlation analysis, positron emission
 tomography, 40:221
 glucose, basal ganglia, 40:115
 glucose metabolism, affective disorder,
 40:195
 glucose metabolism, Alzheimer's disease,
 40:195
 glucose metabolism, anxiety, 35:49, 40:101
 glucose metabolism, apomorphine, 40:135
 glucose metabolism, correlation analysis,
 40:221
 glucose metabolism, hippocampus, 40:195
 glucose metabolism, homovanillic acid, 40:101

Frontal lobe continued

- glucose metabolism, laterality, 35:49
- glucose metabolism, limbic system, 40:221
- glucose metabolism, neuroleptics, 40:115
- glucose metabolism, never-medicated patients, 40:135
- glucose metabolism, obsessive-compulsive disorder, 40:221
- glucose metabolism, positron emission tomography, 35:49, 40:101, 40:115, 40:135, 40:195, 40:221
- glucose metabolism, prolactin, 40:101
- glucose metabolism, schizophrenia, 40:101, 40:115, 40:135
- glucose metabolism, State-Trait Anxiety Inventory, 35:49
- glucose metabolism, temporal lobe, 40:135
- hexamethylpropyleneamineoxime (HMPAO), affective disorder, 40:247
- hexamethylpropyleneamineoxime (HMPAO), limbic system, 40:247
- hexamethylpropyleneamineoxime (HMPAO), single photon emission computed tomography, 40:247
- hexamethylpropyleneamineoxime (HMPAO), sleep, 40:247
- hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
- hippocampus, affective disorder, 40:195
- hippocampus, Alzheimer's disease, 40:195
- hippocampus, glucose metabolism, 40:195
- hippocampus, positron emission tomography, 40:195
- homovanillic acid, anxiety, 40:101
- homovanillic acid, glucose metabolism, 40:101
- homovanillic acid, positron emission tomography, 40:101
- homovanillic acid, prolactin, 40:101
- homovanillic acid, schizophrenia, 40:101
- laterality, anxiety, 35:49
- laterality, glucose metabolism, 35:49
- laterality, positron emission tomography, 35:49
- laterality, State-Trait Anxiety Inventory, 35:49
- limbic system, affective disorder, 40:247
- limbic system, correlation analysis, 40:221
- limbic system, glucose metabolism, 40:221
- limbic system, hexamethylpropyleneamineoxime (HMPAO), 40:247
- limbic system, obsessive-compulsive disorder, 40:247
- limbic system, positron emission tomography, 40:247

Frontal lobe continued

- limbic system, single photon emission computed tomography, 40:247
- limbic system, sleep, 40:247
- limbic system, sleep deprivation, 40:247
- long-term followup, blood flow, 40:253
- long-term followup, schizophrenia, 40:253
- neuroleptics, basal ganglia, 40:115
- neuroleptics, glucose, 40:115
- neuroleptics, positron emission tomography, 40:115
- neuroleptics, schizophrenia, 40:115
- never-medicated patients, apomorphine, 40:135
- never-medicated patients, glucose metabolism, 40:135
- never-medicated patients, positron emission tomography, 40:135
- never-medicated patients, schizophrenia, 40:135
- never-medicated patients, temporal lobe, 40:135
- obsessive-compulsive disorder, correlation analysis, 40:221
- obsessive-compulsive disorder, glucose metabolism, 40:221
- obsessive-compulsive disorder, limbic system, 40:221
- obsessive-compulsive disorder, positron emission tomography, 40:221
- positron emission tomography, affective disorder, 40:195
- positron emission tomography, Alzheimer's disease, 40:195
- positron emission tomography, anxiety, 35:49, 40:101
- positron emission tomography, apomorphine, 40:135
- positron emission tomography, basal ganglia, 40:115
- positron emission tomography, correlation analysis, 40:221
- positron emission tomography, glucose metabolism, 35:49, 40:101, 40:115, 40:135, 40:195, 40:221
- positron emission tomography, hippocampus, 40:195
- positron emission tomography, homovanillic acid, 40:101
- positron emission tomography, laterality, 35:49
- positron emission tomography, limbic system, 40:221
- positron emission tomography, neuroleptics, 40:115
- positron emission tomography, never-medicated patients, 40:135

Frontal lobe continued

positron emission tomography, obsessive-compulsive disorder, 40:221
 positron emission tomography, prolactin, 40:101
 positron emission tomography, schizophrenia, 40:101, 40:115, 40:135
 positron emission tomography, State-Trait Anxiety Inventory, 35:49
 positron emission tomography, temporal lobe, 40:135
 prolactin, anxiety, 40:101
 prolactin, glucose metabolism, 40:101
 prolactin, homovanillic acid, 40:101
 prolactin, positron emission tomography, 40:101
 prolactin, schizophrenia, 40:101
 schizophrenia, anxiety, 40:101
 schizophrenia, apomorphine, 40:135
 schizophrenia, basal ganglia, 40:115
 schizophrenia, blood flow, 35:27, 40:253
 schizophrenia, glucose metabolism, 40:101, 40:115, 40:135
 schizophrenia, homovanillic acid, 40:101
 schizophrenia, long-term followup, 40:253
 schizophrenia, neuroleptics, 40:115
 schizophrenia, never-medicated patients, 40:135
 schizophrenia, positron emission tomography, 40:101, 40:115, 40:135
 schizophrenia, prolactin, 40:101
 schizophrenia, symptom severity, 35:27
 schizophrenia, temporal lobe, 40:135
 single photon emission computed tomography, affective disorder, 40:247
 single photon emission computed tomography, hexamethylpropyleneamineoxime (HMPAO), 40:247
 single photon emission computed tomography, limbic system, 40:247
 single photon emission computed tomography, sleep, 40:247
 single photon emission computed tomography, sleep deprivation, 40:247
 sleep, affective disorder, 40:247
 sleep, hexamethylpropyleneamineoxime (HMPAO), 40:247
 sleep, limbic system, 40:247
 sleep, single photon emission computed tomography, 40:247
 sleep deprivation, affective disorder, 40:247
 sleep deprivation, hexamethylpropyleneamineoxime (HMPAO), 40:247

Frontal lobe continued

sleep deprivation, limbic system, 40:247
 sleep deprivation, single photon emission computed tomography, 40:247
 State-Trait Anxiety Inventory, anxiety, 35:49
 State-Trait Anxiety Inventory, glucose metabolism, 35:49
 State-Trait Anxiety Inventory, laterality, 35:49
 State-Trait Anxiety Inventory, positron emission tomography, 35:49
 symptom severity, blood flow, 35:27
 symptom severity, schizophrenia, 35:27
 temporal lobe, apomorphine, 40:135
 temporal lobe, glucose metabolism, 40:135
 temporal lobe, never-medicated patients, 40:135
 temporal lobe, positron emission tomography, 40:135
 temporal lobe, schizophrenia, 40:135
Gadolinium-DTPA
 blood-brain barrier, cortical sulcal enlargement, 40:203
 blood-brain barrier, magnetic resonance imaging, 40:203
 blood-brain barrier, schizophrenia, 40:203
 blood-brain barrier, ventricular size, 40:203
 cortical sulcal enlargement, blood-brain barrier, 40:203
 cortical sulcal enlargement, magnetic resonance imaging, 40:203
 cortical sulcal enlargement, schizophrenia, 40:203
 cortical sulcal enlargement, ventricular size, 40:203
 magnetic resonance imaging, blood-brain barrier, 40:203
 magnetic resonance imaging, cortical sulcal enlargement, 40:203
 magnetic resonance imaging, schizophrenia, 40:203
 magnetic resonance imaging, ventricular size, 40:203
 schizophrenia, blood-brain barrier, 40:203
 schizophrenia, cortical sulcal enlargement, 40:203
 schizophrenia, magnetic resonance imaging, 40:203
 schizophrenia, ventricular size, 40:203
 ventricular size, blood-brain barrier, 40:203
 ventricular size, cortical sulcal enlargement, 40:203
 ventricular size, magnetic resonance imaging, 40:203
 ventricular size, schizophrenia, 40:203

Gender

hippocampus, schizophrenia, 35:1
schizophrenia, hippocampus, 35:1

Generalized anxiety disorder

blood flow, diazepam, 40:125
blood flow, ondansetron, 40:125
diazepam, blood flow, 40:125
diazepam, ondansetron, 40:125
ondansetron, blood flow, 40:125
ondansetron, diazepam, 40:125

Genetics

admixture analysis, computed tomography, 35:61
admixture analysis, schizophrenia, 35:61
admixture analysis, ventricle-brain ratio, 35:61
amygdala, hippocampus, 35:137
amygdala, magnetic resonance imaging, 35:137
amygdala, schizophrenia, 35:137
amygdala, temporal lobe, 35:137
amygdala, ventricular size, 35:137
computed tomography, admixture analysis, 35:61
computed tomography, schizophrenia, 35:61
computed tomography, ventricle-brain ratio, 35:61
cranial size, magnetic resonance imaging, 40:49
cranial size, schizophrenia, 40:49
cranial size, third ventricle, 40:49
cranial size, ventricular size, 40:49
hippocampus, amygdala, 35:137
hippocampus, magnetic resonance imaging, 35:137
hippocampus, schizophrenia, 35:137
hippocampus, temporal lobe, 35:137
hippocampus, ventricular size, 35:137
magnetic resonance imaging, amygdala, 35:137
magnetic resonance imaging, cranial size, 40:49
magnetic resonance imaging, hippocampus, 35:137
magnetic resonance imaging, schizophrenia, 35:137, 40:49
magnetic resonance imaging, temporal lobe, 35:137
magnetic resonance imaging, third ventricle, 40:49
magnetic resonance imaging, ventricular size, 35:137, 40:49
schizophrenia, admixture analysis, 35:61
schizophrenia, amygdala, 35:137

Genetics continued

schizophrenia, computed tomography, 35:61
schizophrenia, cranial size, 40:49
schizophrenia, hippocampus, 35:137
schizophrenia, magnetic resonance imaging, 35:137, 40:49
schizophrenia, temporal lobe, 35:137
schizophrenia, third ventricle, 40:49
schizophrenia, ventricle-brain ratio, 35:61
schizophrenia, ventricular size, 35:137, 40:49
temporal lobe, amygdala, 35:137
temporal lobe, hippocampus, 35:137
temporal lobe, magnetic resonance imaging, 35:137
temporal lobe, schizophrenia, 35:137
temporal lobe, ventricular size, 35:137
third ventricle, cranial size, 40:49
third ventricle, magnetic resonance imaging, 40:49
third ventricle, schizophrenia, 40:49
third ventricle, ventricular size, 40:49
ventricle-brain ratio, admixture analysis, 35:61
ventricle-brain ratio, computed tomography, 35:61
ventricle-brain ratio, schizophrenia, 35:61
ventricular size, amygdala, 35:137
ventricular size, cranial size, 40:49
ventricular size, hippocampus, 35:137
ventricular size, magnetic resonance imaging, 35:137, 40:49
ventricular size, schizophrenia, 35:137, 40:49
ventricular size, temporal lobe, 35:137
ventricular size, third ventricle, 40:49
Glucose metabolism
affective disorder, Alzheimer's disease, 40:195
affective disorder, frontal lobe, 40:195
affective disorder, hippocampus, 40:195
affective disorder, positron emission tomography, 40:195
Alzheimer's disease, affective disorder, 40:195
Alzheimer's disease, frontal lobe, 40:195
Alzheimer's disease, hippocampus, 40:195
Alzheimer's disease, positron emission tomography, 40:195
anxiety, frontal lobe, 35:49, 40:101
anxiety, homovanillic acid, 40:101
anxiety, laterality, 35:49
anxiety, positron emission tomography, 35:49, 40:101
anxiety, prolactin, 40:101
anxiety, schizophrenia, 40:101
anxiety, State-Trait Anxiety Inventory, 35:49

Glucose metabolism continued
 apomorphine, frontal lobe, 40:135
 apomorphine, never-medicated patients, 40:135
 apomorphine, positron emission tomography, 40:135
 apomorphine, schizophrenia, 40:135
 apomorphine, temporal lobe, 40:135
 basal ganglia, frontal lobe, 40:115
 basal ganglia, neuroleptics, 40:115
 basal ganglia, positron emission tomography, 40:115
 basal ganglia, schizophrenia, 40:115
 correlation analysis, frontal lobe, 40:221
 correlation analysis, limbic system, 40:221
 correlation analysis, obsessive-compulsive disorder, 40:221
 correlation analysis, positron emission tomography, 40:221
 ethanol, positron emission tomography, 35:39
 frontal lobe, affective disorder, 40:195
 frontal lobe, Alzheimer's disease, 40:195
 frontal lobe, anxiety, 35:49, 40:101
 frontal lobe, apomorphine, 40:135
 frontal lobe, basal ganglia, 40:115
 frontal lobe, correlation analysis, 40:221
 frontal lobe, hippocampus, 40:195
 frontal lobe, homovanillic acid, 40:101
 frontal lobe, laterality, 35:49
 frontal lobe, limbic system, 40:221
 frontal lobe, neuroleptics, 40:115
 frontal lobe, never-medicated patients, 40:135
 frontal lobe, obsessive-compulsive disorder, 40:221
 frontal lobe, positron emission tomography, 35:49, 40:101, 40:115, 40:135, 40:195, 40:221
 frontal lobe, prolactin, 40:101
 frontal lobe, schizophrenia, 40:101, 40:115, 40:135
 frontal lobe, State-Trait Anxiety Inventory, 35:49
 frontal lobe, temporal lobe, 40:135
 hippocampus, affective disorder, 40:195
 hippocampus, Alzheimer's disease, 40:195
 hippocampus, frontal lobe, 40:195
 hippocampus, positron emission tomography, 40:195
 homovanillic acid, anxiety, 40:101
 homovanillic acid, frontal lobe, 40:101
 homovanillic acid, positron emission tomography, 40:101

Glucose metabolism, continued
 homovanillic acid, prolactin, 40:101
 homovanillic acid, schizophrenia, 40:101
 laterality, anxiety, 35:49
 laterality, frontal lobe, 35:49
 laterality, positron emission tomography, 35:49
 laterality, State-Trait Anxiety Inventory, 35:49
 limbic system, correlation analysis, 40:221
 limbic system, frontal lobe, 40:221
 limbic system, obsessive-compulsive disorder, 40:221
 limbic system, positron emission tomography, 40:221
 measurement reliability, positron emission tomography, 40:11
 measurement reliability, relative vs. absolute metabolic rate, 40:11
 measurement reliability, schizophrenia, 40:11
 neuroleptics, basal ganglia, 40:115
 neuroleptics, frontal lobe, 40:115
 neuroleptics, positron emission tomography, 40:115
 neuroleptics, schizophrenia, 40:115
 never-medicated patients, apomorphine, 40:135
 never-medicated patients, frontal lobe, 40:135
 never-medicated patients, positron emission tomography, 40:135
 never-medicated patients, schizophrenia, 40:135
 never-medicated patients, temporal lobe, 40:135
 obsessive-compulsive disorder, correlation analysis, 40:221
 obsessive-compulsive disorder, frontal lobe, 40:221
 obsessive-compulsive disorder, limbic system, 40:221
 obsessive-compulsive disorder, positron emission tomography, 40:221
 positron emission tomography, affective disorder, 40:195
 positron emission tomography, Alzheimer's disease, 40:195
 positron emission tomography, anxiety, 35:49, 40:101
 positron emission tomography, apomorphine, 40:135
 positron emission tomography, basal ganglia, 40:115

- Glucose metabolism** continued
 positron emission tomography, correlation analysis, 40:221
 positron emission tomography, ethanol, 35:39
 positron emission tomography, frontal lobe, 35:49, 40:101, 40:115, 40:195, 40:221
 positron emission tomography, hippocampus, 40:195
 positron emission tomography, homovanillic acid, 40:101
 positron emission tomography, laterality, 35:49
 positron emission tomography, limbic system, 40:221
 positron emission tomography, measurement reliability, 40:11
 positron emission tomography, neuroleptics, 40:115
 positron emission tomography, never-medicated patients, 40:135
 positron emission tomography, obsessive-compulsive disorder, 40:221
 positron emission tomography, prolactin, 40:101
 positron emission tomography, relative vs. absolute metabolic rate, 40:11
 positron emission tomography, schizophrenia, 40:11, 40:101, 40:115, 40:135
 positron emission tomography, State-Trait Anxiety Inventory, 35:49
 positron emission tomography, temporal lobe, 40:135
 positron emission tomography, tetrahydrocannabinol, 40:69
 prolactin, anxiety, 40:101
 prolactin, frontal lobe, 40:101
 prolactin, homovanillic acid, 40:101
 prolactin, positron emission tomography, 40:101
 prolactin, schizophrenia, 40:101
 relative vs. absolute metabolic rate, measurement reliability, 40:11
 relative vs. absolute metabolic rate, positron emission tomography, 40:11
 relative vs. absolute metabolic rate, schizophrenia, 40:11
 schizophrenia, anxiety, 40:101
 schizophrenia, apomorphine, 40:135
 schizophrenia, basal ganglia, 40:115
 schizophrenia, frontal lobe, 40:101, 40:115, 40:135
 schizophrenia, homovanillic acid, 40:101
- Glucose metabolism** continued
 schizophrenia, measurement reliability, 40:11
 schizophrenia, neuroleptics, 40:115
 schizophrenia, never-medicated patients, 40:135
 schizophrenia, positron emission tomography, 40:11, 40:101, 40:115, 40:135
 schizophrenia, prolactin, 40:101
 schizophrenia, relative vs. absolute metabolic rate, 40:11
 schizophrenia, temporal lobe, 40:135
 State-Trait Anxiety Inventory, anxiety, 35:49
 State-Trait Anxiety Inventory, frontal lobe, 35:49
 State-Trait Anxiety Inventory, laterality, 35:49
 State-Trait Anxiety Inventory, positron emission tomography, 35:49
 temporal lobe, apomorphine, 40:135
 temporal lobe, frontal lobe, 40:135
 temporal lobe, never-medicated patients, 40:135
 temporal lobe, positron emission tomography, 40:135
 temporal lobe, schizophrenia, 40:135
 tetrahydrocannabinol, positron emission tomography, 40:69
- Haloperidol**
 positron emission tomography, schizophrenia, 40:115
 schizophrenia, positron emission tomography, 40:115
- Hippocampus**
 affective disorder, Alzheimer's disease, 40:195
 affective disorder, frontal lobe, 40:195
 affective disorder, glucose metabolism, 40:195
 affective disorder, positron emission tomography, 40:195
 aging, limbic system, 35:15
 aging, magnetic resonance imaging, 35:15
 aging, ventricular size, 35:15
 Alzheimer's disease, affective disorder, 40:195
 Alzheimer's disease, astrocytosis, 35:149
 Alzheimer's disease, dentate gyrus, 35:149
 Alzheimer's disease, entorhinal cortex, 35:149
 Alzheimer's disease, frontal lobe, 40:195
 Alzheimer's disease, glucose metabolism, 40:195
 Alzheimer's disease, positron emission tomography, 40:195

Hippocampus continued

Alzheimer's disease, post-mortem examination, 35:149
 Alzheimer's disease, schizophrenia, 35:149
 amygdala, genetics, 35:137
 amygdala, magnetic resonance imaging, 35:1, 35:137
 amygdala, schizophrenia, 35:1, 35:137
 amygdala, temporal horn volume, 35:1
 amygdala, temporal lobe, 35:1, 35:137
 amygdala, ventricular size, 35:137
 astrocytosis, Alzheimer's disease, 35:149
 astrocytosis, dentate gyrus, 35:149
 astrocytosis, entorhinal cortex, 35:149
 astrocytosis, post-mortem examination, 35:149
 astrocytosis, schizophrenia, 35:149
 dentate gyrus, Alzheimer's disease, 35:149
 dentate gyrus, astrocytosis, 35:149
 dentate gyrus, entorhinal cortex, 35:149
 dentate gyrus, post-mortem examination, 35:149
 dentate gyrus, schizophrenia, 35:149
 entorhinal cortex, Alzheimer's disease, 35:149
 entorhinal cortex, astrocytosis, 35:149
 entorhinal cortex, dentate gyrus, 35:149
 entorhinal cortex, post-mortem examination, 35:149
 entorhinal cortex, schizophrenia, 35:149
 frontal lobe, affective disorder, 40:195
 frontal lobe, Alzheimer's disease, 40:195
 frontal lobe, glucose metabolism, 40:195
 frontal lobe, positron emission tomography, 40:195
 gender, schizophrenia, 35:1
 genetics, amygdala, 35:137
 genetics, magnetic resonance imaging, 35:137
 genetics, schizophrenia, 35:137
 genetics, temporal lobe, 35:137
 genetics, ventricular size, 35:137
 glucose metabolism, affective disorder, 40:195
 glucose metabolism, Alzheimer's disease, 40:195
 glucose metabolism, frontal lobe, 40:195
 glucose metabolism, positron emission tomography, 40:195
 limbic system, aging, 35:15
 limbic system, magnetic resonance imaging, 35:15
 limbic system, ventricular size, 35:15
 magnetic resonance imaging, aging, 35:15

Hippocampus continued

magnetic resonance imaging, amygdala, 35:1, 35:137
 magnetic resonance imaging, genetics, 35:137
 magnetic resonance imaging, limbic system, 35:15
 magnetic resonance imaging, schizophrenia, 35:1, 35:137
 magnetic resonance imaging, temporal horn volume, 35:1
 magnetic resonance imaging, temporal lobe, 35:1, 35:137
 magnetic resonance imaging, ventricular size, 35:15, 35:137
 positron emission tomography, affective disorder, 40:195
 positron emission tomography, Alzheimer's disease, 40:195
 positron emission tomography, frontal lobe, 40:195
 positron emission tomography, glucose metabolism, 40:195
 post-mortem examination, Alzheimer's disease, 35:149
 post-mortem examination, astrocytosis, 35:149
 post-mortem examination, dentate gyrus, 35:149
 post-mortem examination, entorhinal cortex, 35:149
 post-mortem examination, schizophrenia, 35:149
 schizophrenia, Alzheimer's disease, 35:149
 schizophrenia, amygdala, 35:1, 35:137
 schizophrenia, astrocytosis, 35:149
 schizophrenia, dentate gyrus, 35:149
 schizophrenia, entorhinal cortex, 35:149
 schizophrenia, gender, 35:1
 schizophrenia, genetics, 35:137
 schizophrenia, magnetic resonance imaging, 35:1, 35:137
 schizophrenia, post-mortem examination, 35:149
 schizophrenia, temporal horn volume, 35:1
 schizophrenia, temporal lobe, 35:1, 35:137
 schizophrenia, ventricular size, 35:137
 temporal horn volume, amygdala, 35:1
 temporal horn volume, magnetic resonance imaging, 35:1
 temporal horn volume, schizophrenia, 35:1
 temporal horn volume, temporal lobe, 35:1
 temporal lobe, amygdala, 35:1, 35:137
 temporal lobe, genetics, 35:137

Hippocampus continued

- temporal lobe, magnetic resonance imaging, 35:1, 35:137
- temporal lobe, schizophrenia, 35:1, 35:137
- temporal lobe, temporal horn volume, 35:1
- temporal lobe, ventricular size, 35:137
- ventricular size, aging, 35:15
- ventricular size, amygdala, 35:137
- ventricular size, genetics, 35:137
- ventricular size, limbic system, 35:15
- ventricular size, magnetic resonance imaging, 35:15, 35:137
- ventricular size, schizophrenia, 35:137
- ventricular size, temporal lobe, 35:137
- HMPAO (Hexamethylpropyleneamine-oxime)**
- affective disorder, frontal lobe, 40:247
- affective disorder, limbic system, 40:247
- affective disorder, single photon emission computed tomography, 40:247
- affective disorder, sleep, 40:247
- affective disorder, sleep deprivation, 40:247
- frontal lobe, affective disorder, 40:247
- frontal lobe, limbic system, 40:247
- frontal lobe, single photon emission computed tomography, 40:247
- frontal lobe, sleep, 40:147
- frontal lobe, sleep deprivation, 40:247
- limbic system, affective disorder, 40:247
- limbic system, frontal lobe, 40:247
- limbic system, single photon emission computed tomography, 40:247
- limbic system, sleep, 40:247
- limbic system, sleep deprivation, 40:247
- single photon emission computed tomography, affective disorder, 40:247
- single photon emission computed tomography, frontal lobe, 40:247
- single photon emission computed tomography, limbic system, 40:247
- single photon emission computed tomography, sleep, 40:247
- single photon emission computed tomography, sleep deprivation, 40:247
- sleep, affective disorder, 40:247
- sleep, frontal lobe, 40:247
- sleep, limbic system, 40:247
- sleep, single photon emission computed tomography, 40:247
- sleep deprivation, affective disorder, 40:247
- sleep deprivation, frontal lobe, 40:247
- sleep deprivation, limbic system, 40:247
- sleep deprivation, single photon emission computed tomography, 40:247

Homovanillic acid

- anxiety, frontal lobe, 40:101
- anxiety, glucose metabolism, 40:101
- anxiety, positron emission tomography, 40:101
- anxiety, prolactin, 40:101
- anxiety, schizophrenia, 40:101
- frontal lobe, anxiety, 40:101
- frontal lobe, glucose metabolism, 40:101
- frontal lobe, positron emission tomography, 40:101
- frontal lobe, prolactin, 40:101
- frontal lobe, schizophrenia, 40:101
- glucose metabolism, anxiety, 40:101
- glucose metabolism, frontal lobe, 40:101
- glucose metabolism, positron emission tomography, 40:101
- glucose metabolism, prolactin, 40:101
- glucose metabolism, schizophrenia, 40:101
- positron emission tomography, anxiety, 40:101
- positron emission tomography, frontal lobe, 40:101
- positron emission tomography, glucose metabolism, 40:101
- positron emission tomography, prolactin, 40:101
- positron emission tomography, schizophrenia, 40:101
- prolactin, anxiety, 40:101
- prolactin, frontal lobe, 40:101
- prolactin, glucose metabolism, 40:101
- prolactin, positron emission tomography, 40:101
- prolactin, schizophrenia, 40:101
- schizophrenia, anxiety, 40:101
- schizophrenia, frontal lobe, 40:101
- schizophrenia, glucose metabolism, 40:101
- schizophrenia, positron emission tomography, 40:101
- schizophrenia, prolactin, 40:101
- Human immunodeficiency virus**
- brain size, magnetic resonance imaging, 40:61
- magnetic resonance imaging, brain size, 40:61
- Laterality**
- anxiety, frontal lobe, 35:49
- anxiety, glucose metabolism, 35:49
- anxiety, positron emission tomography, 35:49
- anxiety, State-Trait Anxiety Inventory, 35:49
- cerebral asymmetry, computed tomography, 35:71

Laterality continued

cerebral asymmetry, measurement methods, 35:71
 clomipramine, electroencephalographic topography, 40:91
 clomipramine, evoked potentials, 40:91
 clomipramine, fluoxetine, 40:91
 clomipramine, P300, 40:91
 clomipramine, serotonin, 40:91
 computed tomography, cerebral asymmetry, 35:71
 computed tomography, measurement methods, 35:71
 electroencephalographic topography, clomipramine, 40:91
 electroencephalographic topography, evoked potentials, 40:91
 electroencephalographic topography, fluoxetine, 40:91
 electroencephalographic topography, P300, 40:91
 electroencephalographic topography, serotonin, 40:91
 evoked potentials, clomipramine, 40:91
 evoked potentials, electroencephalographic topography, 40:91
 evoked potentials, fluoxetine, 40:91
 evoked potentials, P300, 40:91
 evoked potentials, serotonin, 40:91
 fluoxetine, clomipramine, 40:91
 fluoxetine, electroencephalographic topography, 40:91
 fluoxetine, evoked potentials, 40:91
 fluoxetine, P300, 40:91
 fluoxetine, serotonin, 40:91
 frontal lobe, anxiety, 35:49
 frontal lobe, glucose metabolism, 35:49
 frontal lobe, positron emission tomography, 35:49
 frontal lobe, State-Trait Anxiety Inventory, 35:49
 glucose metabolism, anxiety, 35:49
 glucose metabolism, frontal lobe, 35:49
 glucose metabolism, positron emission tomography, 35:49
 glucose metabolism, State-Trait Anxiety Inventory, 35:49
 measurement methods, cerebral asymmetry, 35:71
 measurement methods, computed tomography, 35:71
 P300, clomipramine, 40:91
 P300, electroencephalographic topography, 40:91
 P300, evoked potentials, 40:91

Laterality continued

P300, fluoxetine, 40:91
 P300, serotonin, 40:91
 positron emission tomography, anxiety, 35:49
 positron emission tomography, frontal lobe, 35:49
 positron emission tomography, glucose metabolism, 35:49
 positron emission tomography, State-Trait Anxiety Inventory, 35:49
 serotonin, clomipramine, 40:91
 serotonin, electroencephalographic topography, 40:91
 serotonin, evoked potentials, 40:91
 serotonin, fluoxetine, 40:91
 serotonin, P300, 40:91
 State-Trait Anxiety Inventory, anxiety, 35:49
 State-Trait Anxiety Inventory, frontal lobe, 35:49
 State-Trait Anxiety Inventory, glucose metabolism, 35:49
 State-Trait Anxiety Inventory, positron emission tomography, 35:49
Limbic system
 affective disorder, basal ganglia, 40:95
 affective disorder, frontal lobe, 40:247
 affective disorder, hexamethylpropylene-amineoxime (HMPAO), 40:247
 affective disorder, magnetic resonance imaging, 40:95
 affective disorder, putamen, 40:95
 affective disorder, single photon emission computed tomography, 40:247
 affective disorder, sleep, 40:247
 affective disorder, sleep deprivation, 40:247
 aging, hippocampus, 35:15
 aging, magnetic resonance imaging, 35:15
 aging, ventricular size, 35:15
 basal ganglia, affective disorder, 40:95
 basal ganglia, magnetic resonance imaging, 40:95
 basal ganglia, putamen, 40:95
 correlation analysis, frontal lobe, 40:221
 correlation analysis, glucose metabolism, 40:221
 correlation analysis, obsessive-compulsive disorder, 40:221
 correlation analysis, positron emission tomography, 40:221
 frontal lobe, affective disorder, 40:247
 frontal lobe, correlation analysis, 40:221
 frontal lobe, glucose metabolism, 40:221

Limbic system continued

- frontal lobe, hexamethylpropyleneamineoxime (HMPAO), 40:247
- frontal lobe, obsessive-compulsive disorder, 40:221
- frontal lobe, positron emission tomography, 40:221
- frontal lobe, single photon emission computed tomography, 40:247
- frontal lobe, sleep, 40:247
- frontal lobe, sleep deprivation, 40:247
- glucose metabolism, correlation analysis, 40:221
- glucose metabolism, frontal lobe, 40:221
- glucose metabolism, obsessive-compulsive disorder, 40:221
- glucose metabolism, positron emission tomography, 40:221
- hexamethylpropyleneamineoxime (HMPAO), affective disorder, 40:247
- hexamethylpropyleneamineoxime (HMPAO), frontal lobe, 40:247
- hexamethylpropyleneamineoxime (HMPAO), single photon emission computed tomography, 40:247
- hexamethylpropyleneamineoxime (HMPAO), sleep, 40:247
- hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
- hippocampus, aging, 35:15
- hippocampus, magnetic resonance imaging, 35:15
- hippocampus, ventricular size, 35:15
- magnetic resonance imaging, affective disorder, 40:95
- magnetic resonance imaging, aging, 35:15
- magnetic resonance imaging, basal ganglia, 40:95
- magnetic resonance imaging, hippocampus, 35:15
- magnetic resonance imaging, putamen, 40:95
- magnetic resonance imaging, ventricular size, 35:15
- obsessive-compulsive disorder, correlation analysis, 40:247
- obsessive-compulsive disorder, frontal lobe, 40:247
- obsessive-compulsive disorder, glucose metabolism, 40:247
- obsessive-compulsive disorder, positron emission tomography, 40:221
- positron emission tomography, correlation analysis, 40:221
- positron emission tomography, frontal lobe, 40:221
- Limbic system** continued
- positron emission tomography, glucose metabolism, 40:221
- positron emission tomography, obsessive-compulsive disorder, 40:221
- putamen, affective disorder, 40:95
- putamen, basal ganglia, 40:95
- putamen, magnetic resonance imaging, 40:95
- single photon emission computed tomography, affective disorder, 40:247
- single photon emission computed tomography, frontal lobe, 40:247
- single photon emission computed tomography, hexamethylpropyleneamineoxime (HMPAO), 40:247
- single photon emission computed tomography, sleep, 40:247
- single photon emission computed tomography, sleep deprivation, 40:247
- sleep, affective disorder, 40:247
- sleep deprivation, affective disorder, 40:247
- sleep deprivation, frontal lobe, 40:247
- sleep deprivation,

 - hexamethylpropyleneamineoxime (HMPAO), 40:247

- sleep deprivation, single photon emission computed tomography, 40:247
- sleep, frontal lobe, 40:247
- sleep, hexamethylpropyleneamineoxime (HMPAO), 40:247
- sleep, single photon emission computed tomography, 40:247
- ventricular size, aging, 35:15
- ventricular size, hippocampus, 35:15
- ventricular size, magnetic resonance imaging, 35:15

Locus ceruleus

- brain stem reticular formation, neuropathology, 40:31
- brain stem reticular formation, nicotinamide adenosine dinucleotide phosphate, 40:31
- brain stem reticular formation, pedunculopontine nucleus, 40:31
- brain stem reticular formation, schizophrenia, 40:31
- neuropathology, brain stem reticular formation, 40:31
- neuropathology, nicotinamide adenosine dinucleotide phosphate, 40:31
- neuropathology, pedunculopontine nucleus, 40:31
- neuropathology, schizophrenia, 40:31
- nicotinamide adenosine dinucleotide phosphate, brain stem reticular formation, 40:31

Locus ceruleus continued

nicotinamide adenosine dinucleotide phosphate, neuropathology, 40:31
 nicotinamide adenosine dinucleotide phosphate, pedunculopontine nucleus, 40:31
 nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
 pedunculopontine nucleus, brain stem reticular formation, 40:31
 pedunculopontine nucleus, neuropathology, 40:31
 pedunculopontine nucleus, nicotinamide adenosine dinucleotide phosphate, 40:31
 pedunculopontine nucleus, schizophrenia, 40:31
 schizophrenia, brain stem reticular formation, 40:31
 schizophrenia, neuropathology, 40:31
 schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
 schizophrenia, pedunculopontine nucleus, 40:31

Magnetic resonance imaging

affective disorder, aging, 40:211
 affective disorder, basal ganglia, 40:95
 affective disorder, late onset, 40:211
 affective disorder, limbic system, 40:95
 affective disorder, mania, 40:211
 affective disorder, putamen, 40:95
 affective disorder, subcortical hyperintensities, 40:211
 aging, affective disorder, 40:211
 aging, hippocampus, 35:15
 aging, late onset, 40:211
 aging, limbic system, 35:15
 aging, mania, 40:211
 aging, subcortical hyperintensities, 40:211
 aging, ventricular size, 35:15
 amygdala, genetics, 35:137
 amygdala, hippocampus, 35:1, 35:137
 amygdala, schizophrenia, 35:1, 35:137
 amygdala, temporal horn volume, 35:1
 amygdala, temporal lobe, 35:1, 35:137
 amygdala, ventricular size, 35:137
 basal ganglia, affective disorder, 40:95
 basal ganglia, limbic system, 40:95
 basal ganglia, putamen, 40:95
 basal ganglia, schizophrenia, 40:157
 basal ganglia, tardive dyskinesia, 40:157
 blood-brain barrier, cortical sulcal enlargement, 40:203
 blood-brain barrier, gadolinium-DPTA, 40:203

Magnetic resonance imaging continued

blood-brain barrier, schizophrenia, 40:203
 blood-brain barrier, ventricular size, 40:203
 brain volume, computer methods, 40:61
 computer methods, brain volume, 40:61
 cortical sulcal enlargement, blood-brain barrier, 40:203
 cortical sulcal enlargement, gadolinium-DPTA, 40:203
 cortical sulcal enlargement, schizophrenia, 40:203
 cortical sulcal enlargement, ventricular size, 40:203
 cranial size, genetics, 40:49
 cranial size, schizophrenia, 40:49
 cranial size, third ventricle, 40:49
 cranial size, ventricular size, 40:49
 fluorinated neuroleptics, spectroscopy, 35:107
 fluphenazine, pharmacokinetics, 35:107
 fluphenazine, schizophrenia, 35:107
 gadolinium-DPTA, blood-brain barrier, 40:203
 gadolinium-DPTA, cortical sulcal enlargement, 40:203
 gadolinium-DPTA, schizophrenia, 40:203
 gadolinium-DPTA, ventricular size, 40:203
 genetics, amygdala, 35:137
 genetics, cranial size, 40:49
 genetics, hippocampus, 35:137
 genetics, schizophrenia, 35:137, 40:49
 genetics, temporal lobe, 35:137
 genetics, third ventricle, 40:49
 genetics, ventricular size, 35:137, 40:49
 hippocampus, aging, 35:15
 hippocampus, amygdala, 35:1, 35:137
 hippocampus, genetics, 35:137
 hippocampus, limbic system, 35:15
 hippocampus, schizophrenia, 35:1, 35:137
 hippocampus, temporal horn volume, 35:1
 hippocampus, temporal lobe, 35:1, 35:137
 hippocampus, ventricular size, 35:15, 35:137
 late onset, affective disorder, 40:211
 late onset, aging, 40:211
 late onset, mania, 40:211
 late onset, subcortical hyperintensities, 40:211
 limbic system, affective disorder, 40:95
 limbic system, aging, 35:15
 limbic system, basal ganglia, 40:95
 limbic system, hippocampus, 35:15
 limbic system, putamen, 40:95
 limbic system, ventricular size, 35:15
 mania, aging, 40:211

Magnetic resonance imaging continued
 mania, late onset, 40:211
 mania, subcortical hyperintensities, 40:wm
 pharmacokinetics, fluphenazine, 35:107
 pharmacokinetics, schizophrenia, 35:107
 putamen, affective disorder, 40:95
 putamen, basal ganglia, 40:95
 putamen, limbic system, 40:95
 ratio measurement reliability, ventricle-brain ratio, 40:79
 schizophrenia, amygdala, 35:1, 35:137
 schizophrenia, basal ganglia, 40:157
 schizophrenia, blood-brain barrier, 40:203
 schizophrenia, cortical sulcal enlargement, 40:203
 schizophrenia, cranial size, 40:49
 schizophrenia, fluphenazine, 35:107
 schizophrenia, gadolinium-DPTA, 40:203
 schizophrenia, genetics, 35:137, 40:49
 schizophrenia, hippocampus, 35:1, 35:137
 schizophrenia, pharmacokinetics, 35:107
 schizophrenia, T2 hyperintense foci, 40:239
 schizophrenia, tardive dyskinesia, 40:157, 40:239
 schizophrenia, temporal horn volume, 35:1
 schizophrenia, temporal lobe, 35:1, 35:137
 schizophrenia, third ventricle, 40:49
 schizophrenia, ventricular size, 35:137, 40:49, 40:203
 spectroscopy, fluorinated neuroleptics, 35:107
 subcortical hyperintensities, affective disorder, 40:211
 subcortical hyperintensities, aging, 40:211
 subcortical hyperintensities, late onset, 40:211
 subcortical hyperintensities, mania, 40:211
 T2 hyperintense foci, schizophrenia, 40:239
 T2 hyperintense foci, tardive dyskinesia, 40:239
 tardive dyskinesia, basal ganglia, 40:157
 tardive dyskinesia, schizophrenia, 40:157, 40:239
 tardive dyskinesia, T2 hyperintense foci, 40:239
 temporal horn volume, amygdala, 35:1
 temporal horn volume, hippocampus, 35:1
 temporal horn volume, schizophrenia, 35:1
 temporal horn volume, temporal lobe, 35:1
 temporal lobe, amygdala, 35:1, 35:137
 temporal lobe, genetics, 35:137
 temporal lobe, hippocampus, 35:1, 35:137
 temporal lobe, schizophrenia, 35:1, 35:137
 temporal lobe, temporal horn volume, 35:1

Magnetic resonance imaging continued
 temporal lobe, ventricular size, 35:137
 third ventricle, cranial size, 40:49
 third ventricle, genetics, 40:49
 third ventricle, schizophrenia, 40:49
 third ventricle, ventricular size, 40:49
 ventricle-brain ratio, ratio measurement reliability, 40:79
 ventricular size, aging, 35:15
 ventricular size, amygdala, 35:137
 ventricular size, blood-brain barrier, 40:203
 ventricular size, cortical sulcal enlargement, 40:203
 ventricular size, cranial size, 40:49
 ventricular size, gadolinium-DPTA, 40:203
 ventricular size, genetics, 35:137, 40:49
 ventricular size, hippocampus, 35:137, 35:15
 ventricular size, limbic system, 35:15
 ventricular size, schizophrenia, 35:137, 40:49, 40:203
 ventricular size, temporal lobe, 35:137
 ventricular size, third ventricle, 40:49
Neuroleptics
 basal ganglia, frontal lobe, 40:115
 basal ganglia, glucose, 40:115
 basal ganglia, positron emission tomography, 40:115
 basal ganglia, schizophrenia, 40:115
 frontal lobe, basal ganglia, 40:115
 frontal lobe, glucose, 40:115
 frontal lobe, positron emission tomography, 40:115
 frontal lobe, schizophrenia, 40:115
 glucose, basal ganglia, 40:115
 glucose, frontal lobe, 40:115
 glucose, positron emission tomography, 40:115
 glucose, schizophrenia, 40:115
 positron emission tomography, basal ganglia, 40:115
 positron emission tomography, frontal lobe, 40:115
 positron emission tomography, glucose, 40:115
 positron emission tomography, schizophrenia, 40:115
 schizophrenia, basal ganglia, 40:115
 schizophrenia, frontal lobe, 40:115
 schizophrenia, glucose, 40:115
 schizophrenia, positron emission tomography, 40:115
Neuropathology
 Alzheimer's disease, astrocytosis, 35:149
 Alzheimer's disease, schizophrenia, 35:149

Neuropathology continued

- astrocytosis, Alzheimer's disease, 35:149
 - astrocytosis, schizophrenia, 35:149
 - brain stem reticular formation, locus ceruleus, 40:31
 - brain stem reticular formation, nicotinamide adenosine dinucleotide phosphate, 40:31
 - brain stem reticular formation, pedunculopontine nucleus, 40:31
 - brain stem reticular formation, schizophrenia, 40:31
 - locus ceruleus, brain stem reticular formation, 40:31
 - locus ceruleus, nicotinamide adenosine dinucleotide phosphate, 40:31
 - locus ceruleus, pedunculopontine nucleus, 40:31
 - locus ceruleus, schizophrenia, 40:31
 - nicotinamide adenosine dinucleotide phosphate, brain stem reticular formation, 40:31
 - nicotinamide adenosine dinucleotide phosphate, locus ceruleus, 40:31
 - nicotinamide adenosine dinucleotide phosphate, pedunculopontine nucleus, 40:31
 - nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
 - pedunculopontine nucleus, brain stem reticular formation, 40:31
 - pedunculopontine nucleus, locus ceruleus, 40:31
 - pedunculopontine nucleus, nicotinamide adenosine dinucleotide phosphate, 40:31
 - pedunculopontine nucleus, schizophrenia, 40:31
 - schizophrenia, Alzheimer's disease, 35:149
 - schizophrenia, astrocytosis, 35:149
 - schizophrenia, brain stem reticular formation, 40:31
 - schizophrenia, locus ceruleus, 40:31
 - schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
 - schizophrenia, pedunculopontine nucleus, 40:31
- Neuropsychology**
- Alzheimer's disease, computed tomography, 35:115
 - Alzheimer's disease, electroencephalographic topography, 40:181
 - Alzheimer's disease, severity of dementia, 40:181
 - blood flow, Chicago Word Fluency Test, 40:253

Neuropsychology continued

- blood flow, schizophrenia, 40:253
- blood flow, Wisconsin Card Sort Test, 40:253
- Chicago Word Fluency Test, blood flow, 40:253
- computed tomography, Alzheimer's disease, 35:115
- electroencephalographic topography, Alzheimer's disease, 40:181
- electroencephalographic topography, severity of dementia, 40:181
- schizophrenia, blood flow, 40:253
- schizophrenia, Wisconsin Card Sort Test, 40:253
- severity of dementia, Alzheimer's disease, 40:181
- severity of dementia, electroencephalographic topography, 40:181
- Wisconsin Card Sort Test, blood flow, 40:253
- Wisconsin Card Sort Test, schizophrenia, 40:253
- Nicotinamide adenosine dinucleotide phosphate-diaphorase histochemistry
- brain stem reticular formation, locus ceruleus, 40:31
- brain stem reticular formation, neuropathology, 40:31
- brain stem reticular formation, pedunculopontine nucleus, 40:31
- brain stem reticular formation, schizophrenia, 40:31
- locus ceruleus, brain stem reticular formation, 40:31
- locus ceruleus, neuropathology, 40:31
- locus ceruleus, pedunculopontine nucleus, 40:31
- locus ceruleus, schizophrenia, 40:31
- neuropathology, brain stem reticular formation, 40:31
- neuropathology, locus ceruleus, 40:31
- neuropathology, pedunculopontine nucleus, 40:31
- neuropathology, schizophrenia, 40:31
- pedunculopontine nucleus, brain stem reticular formation, 40:31
- pedunculopontine nucleus, locus ceruleus, 40:31
- pedunculopontine nucleus, neuropathology, 40:31
- pedunculopontine nucleus, schizophrenia, 40:31
- post-mortem, schizophrenia, 40:31

- Nicotinamide adenosine dinucleotide phosphate-diaphorase histochemistry continued**
- schizophrenia, brain stem reticular formation, 40:31
- schizophrenia, locus ceruleus, 40:31
- schizophrenia, neuropathology, 40:31
- schizophrenia, pedunculopontine nucleus, 40:31
- schizophrenia, post-mortem, 40:31
- Obsessive-compulsive disorder**
- brain size, magnetic resonance imaging, 40:61
- correlation analysis, frontal lobe, 40:221
- correlation analysis, glucose metabolism, 40:221
- correlation analysis, limbic system, 40:221
- correlation analysis, positron emission tomography, 40:221
- frontal lobe, correlation analysis, 40:221
- frontal lobe, glucose metabolism, 40:221
- frontal lobe, limbic system, 40:221
- frontal lobe, positron emission tomography, 40:221
- glucose metabolism, correlation analysis, 40:221
- glucose metabolism, frontal lobe, 40:221
- glucose metabolism, limbic system, 40:221
- glucose metabolism, positron emission tomography, 40:221
- limbic system, correlation analysis, 40:221
- limbic system, frontal lobe, 40:221
- limbic system, glucose metabolism, 40:221
- limbic system, positron emission tomography, 40:221
- magnetic resonance imaging, brain size, 40:61
- positron emission tomography, correlation analysis, 40:221
- positron emission tomography, frontal lobe, 40:221
- positron emission tomography, glucose metabolism, 40:221
- positron emission tomography, limbic system, 40:221
- Ondansetron**
- anxiety, blood flow, 40:125
- anxiety, diazepam, 40:125
- anxiety, generalized anxiety disorder, 40:125
- blood flow, anxiety, 40:125
- blood flow, diazepam, 40:125
- blood flow, generalized anxiety disorder, 40:125
- diazepam, anxiety, 40:125
- diazepam, blood flow, 40:125
- diazepam, generalized anxiety disorder, 40:125
- generalized anxiety disorder, anxiety, 40:125
- Ondansetron continued**
- generalized anxiety disorder, blood flow, 40:125
- generalized anxiety disorder, diazepam, 40:125
- Pedunculopontine nucleus**
- brain stem reticular formation, locus ceruleus, 40:31
- brain stem reticular formation, neuropathology, 40:31
- brain stem reticular formation, nicotinamide adenosine dinucleotide phosphate, 40:31
- brain stem reticular formation, schizophrenia, 40:31
- locus ceruleus, brain stem reticular formation, 40:31
- locus ceruleus, neuropathology, 40:31
- locus ceruleus, nicotinamide adenosine dinucleotide phosphate, 40:31
- locus ceruleus, schizophrenia, 40:31
- neuropathology, brain stem reticular formation, 40:31
- neuropathology, locus ceruleus, 40:31
- neuropathology, nicotinamide adenosine dinucleotide phosphate, 40:31
- neuropathology, schizophrenia, 40:31
- nicotinamide adenosine dinucleotide phosphate, brain stem reticular formation, 40:31
- nicotinamide adenosine dinucleotide phosphate, locus ceruleus, 40:31
- nicotinamide adenosine dinucleotide phosphate, neuropathology, 40:31
- nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
- schizophrenia, brain stem reticular formation, 40:31
- schizophrenia, locus ceruleus, 40:31
- schizophrenia, neuropathology, 40:31
- schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
- Polysomnography**
- arecoline, electroencephalographic topography, 35:91
- arecoline, sleep, 35:91
- electroencephalographic topography, arecoline, 35:91
- electroencephalographic topography, sleep, 35:91
- sleep, arecoline, 35:91
- sleep, electroencephalographic topography, 35:91
- Positron emission tomography**
- affective disorder, Alzheimer's disease, 40:195

Positron emission tomography continued
 affective disorder, frontal lobe, 40:195
 affective disorder, glucose metabolism,
 40:195
 affective disorder, hippocampus, 40:195
 Alzheimer's disease, affective disorder,
 40:195
 Alzheimer's disease, frontal lobe, 40:195
 Alzheimer's disease, glucose metabolism,
 40:195
 Alzheimer's disease, hippocampus, 40:195
 anxiety, frontal lobe, 35:49, 40:101
 anxiety, glucose metabolism, 35:49, 40:101
 anxiety, homovanillic acid, 40:101
 anxiety, laterality, 35:49
 anxiety, prolactin, 40:101
 anxiety, schizophrenia, 40:101
 anxiety, State-Trait Anxiety Inventory,
 35:49
 apomorphine, frontal lobe, 40:135
 apomorphine, glucose metabolism, 40:135
 apomorphine, never-medicated patients,
 40:135
 apomorphine, schizophrenia, 40:135
 apomorphine, temporal lobe, 40:135
 basal ganglia, glucose, 40:115
 basal ganglia, neuroleptics, 40:115
 basal ganglia, schizophrenia, 40:115
 correlation analysis, frontal lobe, 40:221
 correlation analysis, glucose metabolism,
 40:221
 correlation analysis, limbic system, 40:221
 correlation analysis, obsessive-compulsive
 disorder, 40:221
 ethanol, glucose metabolism, 35:39
 frontal lobe, affective disorder, 40:195
 frontal lobe, Alzheimer's disease, 40:195
 frontal lobe, anxiety, 35:49, 40:101
 frontal lobe, apomorphine, 40:135
 frontal lobe, basal ganglia, 40:115
 frontal lobe, correlation analysis, 40:221
 frontal lobe, glucose, 35:49, 40:101, 40:115,
 40:135, 40:195, 40:221
 frontal lobe, homovanillic acid, 40:101
 frontal lobe, laterality, 35:49
 frontal lobe, limbic system, 40:221
 frontal lobe, neuroleptics, 40:115
 frontal lobe, never-medicated patients,
 40:135
 frontal lobe, obsessive-compulsive disorder,
 40:221
 frontal lobe, prolactin, 40:101
 frontal lobe, schizophrenia, 40:101, 40:115,
 40:135

Positron emission tomography continued
 frontal lobe, State-Trait Anxiety Inventory,
 35:49
 glucose, basal ganglia, 40:115
 glucose, frontal lobe, 40:115
 glucose metabolism, affective disorder, 40:195
 glucose metabolism, Alzheimer's disease,
 40:195
 glucose metabolism, anxiety, 35:49, 40:101
 glucose metabolism, apomorphine, 40:135
 glucose metabolism, correlation analysis,
 40:221
 glucose metabolism, ethanol, 35:39
 glucose metabolism, frontal lobe, 35:49,
 40:101, 40:135, 40:195, 40:221
 glucose metabolism, hippocampus, 40:195
 glucose metabolism, homovanillic acid,
 40:101
 glucose metabolism, laterality, 35:49
 glucose metabolism, limbic system, 40:221
 glucose metabolism, measurement
 reliability, 40:11
 glucose metabolism, never-medicated
 patients, 40:135
 glucose metabolism, obsessive-compulsive
 disorder, 40:221
 glucose metabolism, prolactin, 40:101
 glucose metabolism, relative vs. absolute
 metabolic rate, 40:11
 glucose metabolism, schizophrenia, 40:11,
 40:101, 40:135
 glucose metabolism, State-Trait Anxiety
 Inventory, 35:49
 glucose metabolism, temporal lobe, 40:135
 glucose metabolism, tetrahydrocannabinol,
 40:69
 glucose, neuroleptics, 40:115
 glucose, schizophrenia, 40:115
 haloperidol, schizophrenia, 40:115
 hippocampus, affective disorder, 40:195
 hippocampus, Alzheimer's disease, 40:195
 hippocampus, frontal lobe, 40:195
 hippocampus, glucose metabolism, 40:195
 homovanillic acid, anxiety, 40:101
 homovanillic acid, frontal lobe, 40:101
 homovanillic acid, glucose metabolism,
 40:101
 homovanillic acid, prolactin, 40:101
 homovanillic acid, schizophrenia, 40:101
 laterality, anxiety, 35:49
 laterality, frontal lobe, 35:49
 laterality, glucose metabolism, 35:49
 laterality, State-Trait Anxiety Inventory,
 35:49

- Positron emission tomography** continued
 limbic system, correlation analysis, 40:221
 limbic system, frontal lobe, 40:221
 limbic system, glucose metabolism, 40:221
 limbic system, obsessive-compulsive disorder, 40:221
 measurement reliability, glucose metabolism, 40:11
 measurement reliability, relative vs. absolute metabolic rate, 40:11
 measurement reliability, schizophrenia, 40:11
 neuroleptics, basal ganglia, 40:115
 neuroleptics, frontal lobe, 40:115
 neuroleptics, glucose, 40:115
 neuroleptics, schizophrenia, 40:115
 never-medicated patients, apomorphine, 40:135
 never-medicated patients, frontal lobe, 40:135
 never-medicated patients, glucose metabolism, 40:135
 never-medicated patients, schizophrenia, 40:135
 never-medicated patients, temporal lobe, 40:135
 obsessive-compulsive disorder, correlation analysis, 40:221
 obsessive-compulsive disorder, frontal lobe, 40:221
 obsessive-compulsive disorder, glucose metabolism, 40:221
 obsessive-compulsive disorder, limbic system, 40:221
 prolactin, anxiety, 40:101
 prolactin, frontal lobe, 40:101
 prolactin, glucose metabolism, 40:101
 prolactin, homovanillic acid, 40:101
 prolactin, schizophrenia, 40:101
 relative vs. absolute metabolic rate, glucose metabolism, 40:11
 relative vs. absolute metabolic rate, measurement reliability, 40:11
 relative vs. absolute metabolic rate, schizophrenia, 40:11
 schizophrenia, anxiety, 40:101
 schizophrenia, apomorphine, 40:135
 schizophrenia, basal ganglia, 40:115
 schizophrenia, frontal lobe, 40:101, 40:115, 40:135
 schizophrenia, glucose metabolism, 40:11, 40:101, 40:135
 schizophrenia, haloperidol, 40:115
 schizophrenia, homovanillic acid, 40:101
- Positron emission tomography** continued
 schizophrenia, measurement reliability, 40:11
 schizophrenia, neuroleptics, 40:115
 schizophrenia, never-medicated patients, 40:135
 schizophrenia, prolactin, 40:101
 schizophrenia, relative vs. absolute metabolic rate, 40:11
 schizophrenia, temporal lobe, 40:135
 schizophrenia, thiothixene, 40:115
 State-Trait Anxiety Inventory, anxiety, 35:49
 State-Trait Anxiety Inventory, frontal lobe, 35:49
 State-Trait Anxiety Inventory, glucose metabolism, 35:49
 State-Trait Anxiety Inventory, laterality, 35:49
 temporal lobe, apomorphine, 40:135
 temporal lobe, frontal lobe, 40:135
 temporal lobe, glucose metabolism, 40:135
 temporal lobe, never-medicated patients, 40:135
 temporal lobe, schizophrenia, 40:135
 tetrahydrocannabinol, glucose metabolism, 40:69
 thiothixene, schizophrenia, 40:115
Post-mortem studies. See also Neuro-pathology
 nicotinamide adenosine dinucleotide phosphate, schizophrenia, 40:31
 schizophrenia, nicotinamide adenosine dinucleotide phosphate, 40:31
Prolactin
 anxiety, frontal lobe, 40:101
 anxiety, glucose metabolism, 40:101
 anxiety, homovanillic acid, 40:101
 anxiety, positron emission tomography, 40:101
 anxiety, schizophrenia, 40:101
 frontal lobe, anxiety, 40:101
 frontal lobe, glucose metabolism, 40:101
 frontal lobe, homovanillic acid, 40:101
 frontal lobe, positron emission tomography, 40:101
 frontal lobe, schizophrenia, 40:101
 glucose metabolism, anxiety, 40:101
 glucose metabolism, frontal lobe, 40:101
 glucose metabolism, homovanillic acid, 40:101
 glucose metabolism, positron emission tomography, 40:101
 glucose metabolism, schizophrenia, 40:101

Prolactin continued

- homovanillic acid, anxiety, 40:101
 homovanillic acid, frontal lobe, 40:101
 homovanillic acid, glucose metabolism, 40:101
 homovanillic acid, positron emission tomography, 40:101
 homovanillic acid, schizophrenia, 40:101
 positron emission tomography, anxiety, 40:101
 positron emission tomography, frontal lobe, 40:101
 positron emission tomography, glucose metabolism, 40:101
 positron emission tomography, homovanillic acid, 40:101
 positron emission tomography, schizophrenia, 40:101
 schizophrenia, anxiety, 40:101
 schizophrenia, frontal lobe, 40:101
 schizophrenia, glucose metabolism, 40:101
 schizophrenia, homovanillic acid, 40:101
 schizophrenia, positron emission tomography, 40:101
Schizophrenia
 admixture analysis, computed tomography, 35:61
 admixture analysis, genetics, 35:61
 admixture analysis, ventricle-brain ratio, 35:61
 Alzheimer's disease, astrocytosis, 35:149
 Alzheimer's disease, dentate gyrus, 35:149
 Alzheimer's disease, entorhinal cortex, 35:149
 Alzheimer's disease, hippocampus, 35:149
 Alzheimer's disease, post-mortem examination, 35:149
 amygdala, genetics, 35:137
 amygdala, hippocampus, 35:1, 35:137
 amygdala, magnetic resonance imaging, 35:1, 35:137
 amygdala, temporal horn volume, 35:1
 amygdala, temporal lobe, 35:1, 35:137
 amygdala, ventricular size, 35:137
 anxiety, frontal lobe, 40:101
 anxiety, glucose metabolism, 40:101
 anxiety, homovanillic acid, 40:101
 anxiety, positron emission tomography, 40:101
 anxiety, prolactin, 40:101
 apomorphine, frontal lobe, 40:135
 apomorphine, glucose metabolism, 40:135
 apomorphine, never-medicated patients, 40:135

Schizophrenia continued

- apomorphine, positron emission tomography, 40:135
 apomorphine, temporal lobe, 40:135
 astrocytosis, Alzheimer's disease, 35:149
 astrocytosis, dentate gyrus, 35:149
 astrocytosis, entorhinal cortex, 35:149
 astrocytosis, hippocampus, 35:149
 astrocytosis, post-mortem examination, 35:149
 basal ganglia, frontal lobe, 40:115
 basal ganglia, glucose, 40:115
 basal ganglia, magnetic resonance imaging, 40:157
 basal ganglia, neuroleptics, 40:115
 basal ganglia, positron emission tomography, 40:115
 basal ganglia, tardive dyskinesia, 40:157
 blood-brain barrier, cortical sulcal enlargement, 40:203
 blood-brain barrier, gadolinium-DPTA, 40:203
 blood-brain barrier, magnetic resonance imaging, 40:203
 blood-brain barrier, ventricular size, 40:203
 blood flow, frontal lobe, 35:27, 40:253
 blood flow, long-term followup, 40:253
 blood flow, neuropsychology, 40:253
 blood flow, symptom severity, 35:27
 blood flow, Wisconsin Card Sort Test, 40:253
 brain size, magnetic resonance imaging, 40:61
 brain stem reticular formation, locus ceruleus, 40:31
 brain stem reticular formation, neuropathology, 40:31
 brain stem reticular formation, nicotinamide adenosine dinucleotide phosphate, 40:31
 brain stem reticular formation, pedunculopontine nucleus, 40:31
 computed tomography, admixture analysis, 35:61
 computed tomography, genetics, 35:61
 computed tomography, stability after psychosis onset, 40:21
 computed tomography, ventricle-brain ratio, 35:61
 computed tomography, ventricular size, 40:21
 cortical sulcal enlargement, blood-brain barrier, 40:203
 cortical sulcal enlargement, gadolinium-DPTA, 40:203

- Schizophrenia** continued
 cortical sulcal enlargement, magnetic resonance imaging, 40:203
 cortical sulcal enlargement, ventricular size, 40:203
 cranial size, genetics, 40:49
 cranial size, magnetic resonance imaging, 40:49
 cranial size, third ventricle, 40:49
 cranial size, ventricular size, 40:49
 dentate gyrus, Alzheimer's disease, 35:149
 dentate gyrus, astrocytosis, 35:149
 dentate gyrus, entorhinal cortex, 35:149
 dentate gyrus, hippocampus, 35:149
 dentate gyrus, post-mortem examination, 35:149
 entorhinal cortex, Alzheimer's disease, 35:149
 entorhinal cortex, astrocytosis, 35:149
 entorhinal cortex, dentate gyrus, 35:149
 entorhinal cortex, hippocampus, 35:149
 entorhinal cortex, post-mortem examination, 35:149
 fluphenazine, magnetic resonance spectroscopy, 35:107
 fluphenazine, pharmacokinetics, 35:107
 frontal lobe, anxiety, 40:101
 frontal lobe, apomorphine, 40:135
 frontal lobe, basal ganglia, 40:115
 frontal lobe, blood flow, 35:27, 40:253
 frontal lobe, glucose, 40:115
 frontal lobe, glucose metabolism, 40:101, 40:135
 frontal lobe, homovanillic acid, 40:101
 frontal lobe, long-term followup, 40:253
 frontal lobe, neuroleptics, 40:115
 frontal lobe, never-medicated patients, 40:135
 frontal lobe, positron emission tomography, 40:101, 40:115, 40:135
 frontal lobe, prolactin, 40:101
 frontal lobe, symptom severity, 35:27
 frontal lobe, temporal lobe, 40:135
 gadolinium-DPTA, blood-brain barrier, 40:203
 gadolinium-DPTA, cortical sulcal enlargement, 40:203
 gadolinium-DPTA, magnetic resonance imaging, 40:203
 gadolinium-DPTA, ventricular size, 40:203
 gender, hippocampus, 35:1
 genetics, admixture analysis, 35:61
 genetics, amygdala, 35:137
 genetics, computed tomography, 35:61
Schizophrenia continued
 genetics, cranial size, 40:49
 genetics, hippocampus, 35:137
 genetics, magnetic resonance imaging, 35:137, 40:49
 genetics, temporal lobe, 35:137
 genetics, third ventricle, 40:49
 genetics, ventricle-brain ratio, 35:61
 genetics, ventricular size, 35:137, 40:49
 glucose, basal ganglia, 40:115
 glucose, frontal lobe, 40:115
 glucose metabolism, anxiety, 40:101
 glucose metabolism, apomorphine, 40:135
 glucose metabolism, frontal lobe, 40:101, 40:135
 glucose metabolism, homovanillic acid, 40:101
 glucose metabolism, measurement reliability, 40:11
 glucose metabolism, never-medicated patients, 40:135
 glucose metabolism, positron emission tomography, 40:11, 40:101, 40:135
 glucose metabolism, prolactin, 40:101
 glucose metabolism, relative vs. absolute metabolic rate, 40:11
 glucose metabolism, temporal lobe, 40:135
 glucose, neuroleptics, 40:115
 glucose, positron emission tomography, 40:115
 haloperidol, positron emission tomography, 40:115
 hippocampus, Alzheimer's disease, 35:149
 hippocampus, amygdala, 35:1, 35:137
 hippocampus, astrocytosis, 35:149
 hippocampus, dentate gyrus, 35:149
 hippocampus, entorhinal cortex, 35:149
 hippocampus, gender, 35:1
 hippocampus, genetics, 35:137
 hippocampus, magnetic resonance imaging, 35:1, 35:137
 hippocampus, post-mortem examination, 35:149
 hippocampus, temporal horn volume, 35:1
 hippocampus, temporal lobe, 35:1, 35:137
 hippocampus, ventricular size, 35:137
 homovanillic acid, anxiety, 40:101
 homovanillic acid, frontal lobe, 40:101
 homovanillic acid, glucose metabolism, 40:101
 homovanillic acid, positron emission tomography, 40:101
 homovanillic acid, prolactin, 40:101
 locus ceruleus, brain stem reticular formation, 40:31

Schizophrenia continued

locus ceruleus, nicotinamide adenosine dinucleotide phosphate, 40:31
 locus ceruleus, neuropathology, 40:31
 locus ceruleus, pedunculopontine nucleus, 40:31
 long-term followup, blood flow, 40:253
 long-term followup, frontal lobe, 40:253
 magnetic resonance imaging, amygdala, 35:1, 35:137
 magnetic resonance imaging, basal ganglia, 40:157
 magnetic resonance imaging, blood-brain barrier, 40:203
 magnetic resonance imaging, brain size, 40:61
 magnetic resonance imaging, cortical sulcal enlargement, 40:203
 magnetic resonance imaging, cranial size, 40:49
 magnetic resonance imaging, gadolinium-DPTA, 40:203
 magnetic resonance imaging, genetics, 35:137, 40:49
 magnetic resonance imaging, hippocampus, 35:1, 35:137
 magnetic resonance imaging, T2 hyperintense foci, 40:239
 magnetic resonance imaging, tardive dyskinesia, 40:157, 40:239
 magnetic resonance imaging, temporal horn volume, 35:1
 magnetic resonance imaging, temporal lobe, 35:1, 35:137
 magnetic resonance imaging, third ventricle, 40:49
 magnetic resonance imaging, ventricular size, 35:137, 40:49, 40:203
 magnetic resonance spectroscopy, fluphenazine, 35:107
 magnetic resonance spectroscopy, pharmacokinetics, 35:107
 measurement reliability, glucose metabolism, 40:11
 measurement reliability, positron emission tomography, 40:11
 measurement reliability, relative vs. absolute metabolic rate, 40:11
 neuroleptics, basal ganglia, 40:115
 neuroleptics, frontal lobe, 40:115
 neuroleptics, glucose, 40:115
 neuroleptics, positron emission tomography, 40:115
 neuropathology, brain stem reticular formation, 40:31

Schizophrenia continued

neuropathology, locus ceruleus, 40:31
 neuropathology, nicotinamide adenosine dinucleotide phosphate, 40:31
 neuropathology, pedunculopontine nucleus, 40:31
 neuropsychology, blood flow, 40:253
 neuropsychology, Wisconsin Card Sort Test, 40:253
 never-medicated patients, apomorphine, 40:135
 never-medicated patients, frontal lobe, 40:135
 never-medicated patients, glucose metabolism, 40:135
 never-medicated patients, positron emission tomography, 40:135
 never-medicated patients, temporal lobe, 40:135
 nicotinamide adenosine dinucleotide phosphate, brain stem reticular formation, 40:31
 nicotinamide adenosine dinucleotide phosphate, locus ceruleus, 40:31
 nicotinamide adenosine dinucleotide phosphate, neuropathology, 40:31
 nicotinamide adenosine dinucleotide phosphate, pedunculopontine nucleus, 40:31
 nicotinamide adenosine dinucleotide phosphate, post-mortem, 40:31
 pedunculopontine nucleus, brain stem reticular formation, 40:31
 pedunculopontine nucleus, locus ceruleus, 40:31
 pedunculopontine nucleus, neuropathology, 40:31
 pedunculopontine nucleus, nicotinamide adenosine dinucleotide phosphate, 40:31
 pharmacokinetics, fluphenazine, 35:107
 pharmacokinetics, magnetic resonance spectroscopy, 35:107
 positron emission tomography, anxiety, 40:101
 positron emission tomography, apomorphine, 40:135
 positron emission tomography, basal ganglia, 40:115
 positron emission tomography, frontal lobe, 40:101, 40:115, 40:135
 positron emission tomography, glucose metabolism, 40:11, 40:101, 40:115, 40:135
 positron emission tomography, haloperidol, 40:115

- Schizophrenia** continued
 positron emission tomography, homovanillic acid, 40:101
 positron emission tomography, measurement reliability, 40:11
 positron emission tomography, neuroleptics, 40:115
 positron emission tomography, never-medicated patients, 40:135
 positron emission tomography, prolactin, 40:101
 positron emission tomography, relative vs. absolute metabolic rate, 40:11
 positron emission tomography, temporal lobe, 40:135
 positron emission tomography, thiothixene, 40:115
 post-mortem examination, Alzheimer's disease, 35:149
 post-mortem examination, astrocytosis, 35:149
 post-mortem examination, dentate gyrus, 35:149
 post-mortem examination, entorhinal cortex, 35:149
 post-mortem examination, hippocampus, 35:149
 post-mortem, nicotinamide adenine dinucleotide phosphate, 40:31
 prolactin, anxiety, 40:101
 prolactin, frontal lobe, 40:101
 prolactin, glucose metabolism, 40:101
 prolactin, homovanillic acid, 40:101
 prolactin, positron emission tomography, 40:101
 relative vs. absolute metabolic rate, glucose metabolism, 40:11
 relative vs. absolute metabolic rate, measurement reliability, 40:11
 relative vs. absolute metabolic rate, positron emission tomography, 40:11
 stability after psychosis onset, computed tomography, 40:21
 stability after psychosis onset, ventricular size, 40:21
 symptom severity, blood flow, 35:27
 symptom severity, frontal lobe, 35:27
 T2 hyperintense foci, magnetic resonance imaging, 40:239
 T2 hyperintense foci, tardive dyskinesia, 40:239
 tardive dyskinesia, basal ganglia, 40:157
 tardive dyskinesia, magnetic resonance imaging, 40:157
- Schizophrenia** continued
 tardive dyskinesia, magnetic resonance imaging, 40:239
 tardive dyskinesia, T2 hyperintense foci, 40:239
 temporal horn volume, amygdala, 35:1
 temporal horn volume, hippocampus, 35:1
 temporal horn volume, magnetic resonance imaging, 35:1
 temporal horn volume, temporal lobe, 35:1
 temporal lobe, amygdala, 35:1, 35:137
 temporal lobe, apomorphine, 40:135
 temporal lobe, frontal lobe, 40:135
 temporal lobe, genetics, 35:137
 temporal lobe, glucose metabolism, 40:135
 temporal lobe, hippocampus, 35:1
 35:137
 temporal lobe, magnetic resonance imaging, 35:1, 35:137
 temporal lobe, never-medicated patients, 40:135
 temporal lobe, positron emission tomography, 40:135
 temporal lobe, temporal horn volume, 35:1
 temporal lobe, ventricular size, 35:137
 thiothixene, positron emission tomography, 40:115
 third ventricle, cranial size, 40:49
 third ventricle, genetics, 40:49
 third ventricle, magnetic resonance imaging, 40:49
 third ventricle, ventricular size, 40:49
 ventricle-brain ratio, admixture analysis, 35:61
 ventricle-brain ratio, computed tomography, 35:61
 ventricle-brain ratio, genetics, 35:61
 ventricular size, amygdala, 35:137
 ventricular size, blood-brain barrier, 40:203
 ventricular size, computed tomography, 40:21
 ventricular size, cortical sulcal enlargement, 40:203
 ventricular size, cranial size, 40:49
 ventricular size, gadolinium-DPTA, 40:203
 ventricular size, genetics, 35:137
 ventricular size, genetics, 40:49
 ventricular size, hippocampus, 35:137
 ventricular size, magnetic resonance imaging, 35:137, 40:49, 40:203
 ventricular size, stability after psychosis onset, 40:21
 ventricular size, temporal lobe, 35:137
 ventricular size, third ventricle, 40:49

Schizophrenia continued

Wisconsin Card Sort Test, blood flow, 40:253
 Wisconsin Card Sort Test, neuropsychology,
 40:253

Serotonin

clomipramine, electroencephalographic
 topography, 40:91
 clomipramine, evoked potentials, 40:91
 clomipramine, fluoxetine, 40:91
 clomipramine, laterality, 40:91
 clomipramine, P300, 40:91
 electroencephalographic topography,
 clomipramine, 40:91
 electroencephalographic topography, evoked
 potentials, 40:91
 electroencephalographic topography,
 fluoxetine, 40:91
 electroencephalographic topography,
 laterality, 40:91
 electroencephalographic topography, P300,
 40:91
 evoked potentials, clomipramine, 40:91
 evoked potentials, electroencephalographic
 topography, 40:91
 evoked potentials, fluoxetine, 40:91
 evoked potentials, laterality, 40:91
 evoked potentials, P300, 40:91
 fluoxetine, clomipramine, 40:91
 fluoxetine, electroencephalographic
 topography, 40:91
 fluoxetine, evoked potentials, 40:91
 fluoxetine, laterality, 40:91
 fluoxetine, P300, 40:91
 laterality, clomipramine, 40:91
 laterality, electroencephalographic
 topography, 40:91
 laterality, evoked potentials, 40:91
 laterality, fluoxetine, 40:91
 laterality, P300, 40:91
 P300, clomipramine, 40:91
 P300, electroencephalographic topography,
 40:91
 P300, evoked potentials, 40:91
 P300, fluoxetine, 40:91
 P300, laterality, 40:91
Sleep

affective disorder, frontal lobe, 40:247
 affective disorder,
 hexamethylpropyleneamineoxime (HMPAO),
 40:247
 affective disorder, limbic system, 40:247
 affective disorder, single photon emission
 computed tomography, 40:247
 affective disorder, sleep deprivation, 40:247

Sleep continued

arecoline, electroencephalographic
 topography, 35:91
 arecoline, polysomnography, 35:91
 electroencephalographic topography,
 arecoline, 35:91
 electroencephalographic topography,
 polysomnography, 35:91
 frontal lobe, affective disorder, 40:247
 frontal lobe, hexamethylpropyleneamine-
 oxime (HMPAO), 40:247
 frontal lobe, limbic system, 40:247
 frontal lobe, single photon emission
 computed tomography, 40:247
 frontal lobe, sleep deprivation, 40:247
 hexamethylpropyleneamineoxime (HMPAO),
 affective disorder, 40:247
 hexamethylpropyleneamineoxime (HMPAO),
 frontal lobe, 40:247
 hexamethylpropyleneamineoxime (HMPAO),
 limbic system, 40:247
 hexamethylpropyleneamineoxime (HMPAO),
 single photon emission computed
 hexamethylpropyleneamineoxime (HMPAO),
 sleep deprivation, 40:247
 tomography, 40:247
 limbic system, affective disorder, 40:247
 limbic system, frontal lobe, 40:247
 limbic system, hexamethylpropyleneamine-
 oxime (HMPAO), 40:247
 limbic system, single photon emission
 computed tomography, 40:247
 limbic system, sleep deprivation, 40:247
 polysomnography, arecoline, 35:91
 polysomnography, electroencephalographic
 topography, 35:91
 single photon emission computed tomog-
 raphy, affective disorder, 40:247
 single photon emission computed tomog-
 raphy, frontal lobe, 40:247
 single photon emission computed tomog-
 raphy, hexamethylpropyleneamineoxime
 (HMPAO), 40:247
 single photon emission computed
 tomography, limbic system, 40:247
 single photon emission computed
 tomography, sleep deprivation, 40:247
 sleep deprivation, affective disorder, 40:247
 sleep deprivation, frontal lobe, 40:247
 sleep deprivation, hexamethylpropylene-
 amineoxime (HMPAO), 40:247
 sleep deprivation, limbic system, 40:247
 sleep deprivation, single photon emission
 computed tomography, 40:247

- SPECT (Single photon emission tomography)**
- affective disorder, frontal lobe, 40:247
 - affective disorder, hexamethylpropylene-amineoxime (HMPAO), 40:247
 - affective disorder, limbic system, 40:247
 - affective disorder, sleep, 40:247
 - affective disorder, sleep deprivation, 40:247
 - Alzheimer's disease, blood flow, 40:167
 - Alzheimer's disease, cortical circumferential analysis, 40:167
 - Alzheimer's disease, iodoamphetamine, 40:167
 - blood flow, Alzheimer's disease, 40:167
 - blood flow, cortical circumferential analysis, 40:167
 - blood flow, iodoamphetamine, 40:167
 - cortical circumferential analysis, Alzheimer's disease, 40:167
 - cortical circumferential analysis, blood flow, 40:167
 - cortical circumferential analysis, iodoamphetamine, 40:167
 - frontal lobe, affective disorder, 40:247
 - frontal lobe, hexamethylpropylene-amineoxime (HMPAO), 40:247
 - frontal lobe, limbic system, 40:247
 - frontal lobe, sleep deprivation, 40:247
 - hexamethylpropyleneamineoxime (HMPAO), affective disorder, 40:247
 - hexamethylpropyleneamineoxime (HMPAO), frontal lobe, 40:247
 - hexamethylpropyleneamineoxime (HMPAO), limbic system, 40:247
 - hexamethylpropyleneamineoxime (HMPAO), sleep, 40:247
 - hexamethylpropyleneamineoxime (HMPAO), sleep deprivation, 40:247
 - iodoamphetamine, Alzheimer's disease, 40:167
 - iodoamphetamine, blood flow, 40:167
 - iodoamphetamine, cortical circumferential analysis, 40:167
 - limbic system, affective disorder, 40:247
 - limbic system, frontal lobe, 40:247
 - limbic system, hexamethylpropylene-amineoxime (HMPAO), 40:247
 - limbic system, sleep deprivation, 40:247
 - sleep, affective disorder, 40:247
 - sleep deprivation, affective disorder, 40:247
 - sleep deprivation, frontal lobe, 40:247
 - sleep deprivation, hexamethylpropylene-amineoxime (HMPAO), 40:247
 - sleep deprivation, limbic system, 40:247
 - sleep deprivation, sleep, 40:247
 - sleep, frontal lobe, 40:247
- SPECT (Single photon emission tomography) continued**
- sleep, hexamethylpropyleneamineoxime (HMPAO), 40:247
 - sleep, limbic system, 40:247
 - sleep, sleep deprivation, 40:247
- Substance abuse**
- alpha power, Beck Depression Scale, 35:95
 - alpha power, cocaine, 35:95
 - alpha power, electroencephalographic topography, 35:95
 - Beck Depression Scale, alpha power, 35:95
 - Beck Depression Scale, cocaine, 35:95
 - Beck Depression Scale, electroencephalographic topography, 35:95
 - cocaine, alpha power, 35:95
 - cocaine, Beck Depression Scale, 35:95
 - cocaine, electroencephalographic topography, 35:95
 - electroencephalographic topography, alpha power, 35:95
 - electroencephalographic topography, Beck Depression Scale, 35:95
 - electroencephalographic topography, cocaine, 35:95
- Tardive dyskinesia**
- basal ganglia, magnetic resonance imaging, 40:157
 - basal ganglia, schizophrenia, 40:157
 - magnetic resonance imaging, basal ganglia, 40:157
 - magnetic resonance imaging, schizophrenia, 40:157, 40:239
 - magnetic resonance imaging, T2 hyperintense foci, 40:239
 - schizophrenia, basal ganglia, 40:157
 - schizophrenia, magnetic resonance imaging, 40:157, 40:239
 - schizophrenia, T2 hyperintense foci, 40:239
 - T2 hyperintense foci, magnetic resonance imaging, 40:239
 - T2 hyperintense foci, schizophrenia, 40:239
- Temporal lobe**
- amygdala, genetics, 35:137
 - amygdala, hippocampus, 35:1, 35:137
 - amygdala, magnetic resonance imaging, 35:1, 35:137
 - amygdala, schizophrenia, 35:1, 35:137
 - amygdala, temporal horn volume, 35:1
 - amygdala, ventricular size, 35:137
 - apomorphine, frontal lobe, 40:135
 - apomorphine, glucose metabolism, 40:135
 - apomorphine, never-medicated patients, 40:135

Temporal lobe continued

- apomorphine, positron emission tomography, 40:135
- apomorphine, schizophrenia, 40:135
- frontal lobe, apomorphine, 40:135
- frontal lobe, glucose metabolism, 40:135
- frontal lobe, never-medicated patients, 40:135
- frontal lobe, positron emission tomography, 40:135
- frontal lobe, schizophrenia, 40:135
- genetics, amygdala, 35:137
- genetics, hippocampus, 35:137
- genetics, magnetic resonance imaging, 35:137
- genetics, schizophrenia, 35:137
- genetics, ventricular size, 35:137
- glucose metabolism, apomorphine, 40:135
- glucose metabolism, frontal lobe, 40:135
- glucose metabolism, never-medicated patients, 40:135
- glucose metabolism, positron emission tomography, 40:135
- glucose metabolism, schizophrenia, 40:135
- hippocampus, amygdala, 35:1, 35:137
- hippocampus, genetics, 35:137
- hippocampus, magnetic resonance imaging, 35:1, 35:137
- hippocampus, schizophrenia, 35:1, 35:137
- hippocampus, temporal horn volume, 35:1
- hippocampus, ventricular size, 35:137
- magnetic resonance imaging, amygdala, 35:1, 35:137
- magnetic resonance imaging, genetics, 35:137
- magnetic resonance imaging, hippocampus, 35:1, 35:137
- magnetic resonance imaging, schizophrenia, 35:1, 35:137
- magnetic resonance imaging, temporal horn volume, 35:1
- magnetic resonance imaging, ventricular size, 35:137
- never-medicated patients, apomorphine, 40:135
- never-medicated patients, frontal lobe, 40:135
- never-medicated patients, glucose metabolism, 40:135
- never-medicated patients, positron emission tomography, 40:135
- never-medicated patients, schizophrenia, 40:135
- positron emission tomography, apomorphine, 40:135

Temporal lobe continued

- positron emission tomography, frontal lobe, 40:135
- positron emission tomography, glucose metabolism, 40:135
- positron emission tomography, never-medicated patients, 40:135
- positron emission tomography, schizophrenia, 40:135
- schizophrenia, amygdala, 35:1, 35:137
- schizophrenia, apomorphine, 40:135
- schizophrenia, frontal lobe, 40:135
- schizophrenia, genetics, 35:137
- schizophrenia, glucose metabolism, 40:135
- schizophrenia, hippocampus, 35:1, 35:137
- schizophrenia, magnetic resonance imaging, 35:1, 35:137
- schizophrenia, never-medicated patients, 40:135
- schizophrenia, positron emission tomography, 40:135
- schizophrenia, temporal horn volume, 35:1
- schizophrenia, ventricular size, 35:137
- temporal horn volume, amygdala, 35:1
- temporal horn volume, hippocampus, 35:1
- temporal horn volume, magnetic resonance imaging, 35:1
- temporal horn volume, schizophrenia, 35:1
- ventricular size, amygdala, 35:137
- ventricular size, genetics, 35:137
- ventricular size, hippocampus, 35:137
- ventricular size, magnetic resonance imaging, 35:137
- ventricular size, schizophrenia, 35:137
- Tetrahydrocannabinol**
- glucose metabolism, positron emission tomography, 40:69
- positron emission tomography, glucose metabolism, 40:69
- Thiothixene**
- positron emission tomography, schizophrenia, 40:115
- schizophrenia, positron emission tomography, 40:115
- Ventricle-brain ratio**
- admixture analysis, computed tomography, 35:61
- admixture analysis, genetics, 35:61
- admixture analysis, schizophrenia, 35:61
- aging, Alzheimer's disease, 35:115
- aging, cognition, 35:115
- aging, computed tomography, 35:115
- aging, hippocampus, 35:15
- aging, limbic system, 35:15

- Ventrie-brain ratio continued**
- aging, magnetic resonance imaging, 35:15
 - aging, Mini-Mental State Examination, 35:115
 - aging, Wechsler Adult Intelligence Scale, 35:115
 - alcoholism, computed tomography, 40:1
 - alcoholism, measurement reliability, 40:1
 - Alzheimer's disease, aging, 35:115
 - Alzheimer's disease, cognition, 35:115
 - Alzheimer's disease, computed tomography, 35:115
 - Alzheimer's disease, Mini-Mental State Examination, 35:115
 - Alzheimer's disease, Wechsler Adult Intelligence Scale, 35:115
 - amygdala, genetics, 35:137
 - amygdala, hippocampus, 35:137
 - amygdala, magnetic resonance imaging, 35:137
 - amygdala, schizophrenia, 35:137
 - amygdala, temporal lobe, 35:137
 - blood-brain barrier, cortical sulcal enlargement, 40:203
 - blood-brain barrier, gadolinium-DPTA, 40:203
 - blood-brain barrier, magnetic resonance imaging, 40:203
 - blood-brain barrier, schizophrenia, 40:203
 - cognition, aging, 35:115
 - cognition, Alzheimer's disease, 35:115
 - cognition, computed tomography, 35:115
 - cognition, Mini-Mental State Examination, 35:115
 - cognition, Wechsler Adult Intelligence Scale, 35:115
 - computed tomography, admixture analysis, 35:61
 - computed tomography, aging, 35:115
 - computed tomography, alcoholism, 40:1
 - computed tomography, Alzheimer's disease, 35:115
 - computed tomography, cognition, 35:115
 - computed tomography, genetics, 35:61
 - computed tomography, measurement reliability, 40:1
 - computed tomography, Mini-Mental State Examination, 35:115
 - computed tomography, schizophrenia, 35:61, 40:21
 - computed tomography, stability after psychosis onset, 40:21
 - computed tomography, Wechsler Adult Intelligence Scale, 35:115
- Ventrie-brain ratio continued**
- cortical sulcal enlargement, blood-brain barrier, 40:203
 - cortical sulcal enlargement, gadolinium-DPTA, 40:203
 - cortical sulcal enlargement, magnetic resonance imaging, 40:203
 - cortical sulcal enlargement, schizophrenia, 40:203
 - cranial size, genetics, 40:49
 - cranial size, magnetic resonance imaging, 40:49
 - cranial size, schizophrenia, 40:49
 - cranial size, third ventricle, 40:49
 - gadolinium-DPTA, blood-brain barrier, 40:203
 - gadolinium-DPTA, cortical sulcal enlargement, 40:203
 - gadolinium-DPTA, magnetic resonance imaging, 40:203
 - gadolinium-DPTA, schizophrenia, 40:203
 - genetics, admixture analysis, 35:61
 - genetics, amygdala, 35:137
 - genetics, computed tomography, 35:61
 - genetics, cranial size, 40:49
 - genetics, hippocampus, 35:137
 - genetics, magnetic resonance imaging, 35:137, 40:49
 - genetics, schizophrenia, 35:61, 35:137, 40:49
 - genetics, temporal lobe, 35:137
 - genetics, third ventricle, 40:49
 - hippocampus, aging, 35:15
 - hippocampus, amygdala, 35:137
 - hippocampus, genetics, 35:137
 - hippocampus, limbic system, 35:15
 - hippocampus, magnetic resonance imaging, 35:15, 35:137
 - hippocampus, schizophrenia, 35:137
 - hippocampus, temporal lobe, 35:137
 - limbic system, aging, 35:15
 - limbic system, hippocampus, 35:15
 - limbic system, magnetic resonance imaging, 35:15
 - magnetic resonance imaging, aging, 35:15
 - magnetic resonance imaging, amygdala, 35:137
 - magnetic resonance imaging, blood-brain barrier, 40:203
 - magnetic resonance imaging, cortical sulcal enlargement, 40:203
 - magnetic resonance imaging, cranial size, 40:49
 - magnetic resonance imaging, gadolinium-DPTA, 40:203

Venticle-brain ratio continued

- magnetic resonance imaging, genetics, 35:137
- magnetic resonance imaging, genetics, 40:49
- magnetic resonance imaging, hippocampus, 35:15, 35:137
- magnetic resonance imaging, limbic system, 35:15
- magnetic resonance imaging, ratio measurement reliability, 40:79
- magnetic resonance imaging, schizophrenia, 35:137, 40:49, 40:203
- magnetic resonance imaging, temporal lobe, 35:137
- magnetic resonance imaging, third ventricle, 40:49
- measurement reliability, alcoholism, 40:1
- measurement reliability, computed tomography, 40:1
- Mini-Mental State Examination, aging, 35:115**
- Mini-Mental State Examination, Alzheimer's disease, 35:115
- Mini-Mental State Examination, cognition, 35:115
- Mini-Mental State Examination, computed tomography, 35:115
- Mini-Mental State Examination, Wechsler Adult Intelligence Scale, 35:115
- ratio measurement reliability, magnetic resonance imaging, 40:79
- schizophrenia, admixture analysis, 35:61
- schizophrenia, amygdala, 35:137
- schizophrenia, blood-brain barrier, 40:203
- schizophrenia, computed tomography, 35:61, 40:21
- schizophrenia, cortical sulcal enlargement, 40:203

Venticle-brain ratio continued

- schizophrenia, cranial size, 40:49
- schizophrenia, gadolinium-DPTA, 40:203
- schizophrenia, genetics, 35:61, 35:137
- 40:49
- schizophrenia, hippocampus, 35:137
- schizophrenia, magnetic resonance imaging, 35:137, 40:49, 40:203
- schizophrenia, stability after psychosis onset, 40:21
- schizophrenia, temporal lobe, 35:137
- schizophrenia, third ventricle, 40:49
- stability after psychosis onset, computed tomography, 40:21
- stability after psychosis onset, schizophrenia, 40:21
- temporal lobe, amygdala, 35:137
- temporal lobe, genetics, 35:137
- temporal lobe, hippocampus, 35:137
- temporal lobe, magnetic resonance imaging, 35:137
- temporal lobe, schizophrenia, 35:137
- third ventricle, cranial size, 40:49
- third ventricle, genetics, 40:49
- third ventricle, magnetic resonance imaging, 40:49
- third ventricle, schizophrenia, 40:49
- Wechsler Adult Intelligence Scale, aging, 35:115
- Wechsler Adult Intelligence Scale, Alzheimer's disease, 35:115
- Wechsler Adult Intelligence Scale, cognition, 35:115
- Wechsler Adult Intelligence Scale, computed tomography, 35:115
- Wechsler Adult Intelligence Scale, Mini-Mental State Examination, 35:115